



Australian Government

Department of Health and Ageing

SCHEDULE OF PHARMACEUTICAL BENEFITS FOR DENTAL PRACTITIONERS

This Schedule is also available on the internet at

www.pbs.gov.au

EFFECTIVE 1 AUGUST 2009 -

31 AUGUST 2009

(ALL PREVIOUS EDITIONS CANCELLED)

© Commonwealth of Australia 2009
ISSN 1037-3675

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney General's Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at <http://www.ag.gov.au/cca>

This Schedule provides information on the arrangements for the prescribing and supply of pharmaceutical benefits. These arrangements operate under the *National Health Act 1953*. However, at the time of printing, the relevant legislation giving authority for the changes included in this issue of the Schedule may still be subject to the usual Parliamentary scrutiny. This book is not a legal document, and, in cases of discrepancy, the legislation will be the source document for payment for the supply of pharmaceutical benefits. The legislation is available from the Federal Register of Legislative Instruments website at <http://www.frli.gov.au>.

CONTENTS

| | |
|--|----|
| SUMMARY OF CHANGES | 4 |
| SECTION 1 - EXPLANATORY NOTES | 6 |
| Introduction | 6 |
| 1. The Schedule — Where to Find What | 6 |
| Section 1 | 6 |
| Section 2 | 6 |
| 2. Prescribing Medicines — Information for Dentists | 7 |
| Eligible prescribers | 7 |
| PBS prescription forms | 7 |
| Ordering forms | 7 |
| Preparing general prescriptions | 7 |
| Do's and don't's | 7 |
| Writing the PBS prescription | 8 |
| Restrictions | 8 |
| Maximum quantities | 8 |
| Urgent cases | 8 |
| 3. Patient Charges | 9 |
| Type of patient | 9 |
| What patients pay | 9 |
| Patient contribution | 9 |
| Patient contributions for early supply of some PBS medicines | 9 |
| Brand premiums | 10 |
| Solvents | 10 |
| 4. RPBS Dental Prescribing | 10 |
| ADDRESSES - MEDICARE AUSTRALIA | 11 |
| INDEX OF MANUFACTURERS' CODES | 12 |
| THERAPEUTIC INDEX | 17 |
| SECTION 2 | 21 |
| Symbols used in the Schedule | 22 |
| Special Pharmaceutical Benefits | 24 |
| | 25 |
| Schedule of Benefits | 25 |
| GENERIC/PROPRIETARY INDEX | 55 |

PHARMACEUTICAL BENEFITS

These changes to the Schedule of Pharmaceutical Benefits for Dental Practitioners are effective from 1 August 2009. The Schedule is updated on the first day of each month and is available on the Internet at www.pbs.gov.au.

SUMMARY OF CHANGES

ADDITIONS

Additions — Items

- 5005K **Glucose**, I.V. infusion 139 mmol (anhydrous) per 500 mL (5%), 500 mL (*BR, PK*)
 5021G **Sodium chloride**, I.V. infusion 77 mmol per 500 mL (0.9%), 500 mL (*BR, PK*)

Additions — Brands

- 5008N *APO-Amoxicillin/Clavulanic Acid 500/125, TX* — **Amoxicillin with clavulanic acid**, Tablet 500 mg-125 mg
 5009P *Curam, SZ* — **Amoxicillin with clavulanic acid**, Powder for syrup 125 mg-31.25 mg per 5 mL, 75 mL
 5011R *Curam Duo, SZ* — **Amoxicillin with clavulanic acid**, Powder for syrup 400 mg-57 mg per 5 mL, 60 mL
 3316M *APO-Paracetamol/Codeine/500/30, TX* — **Codeine phosphate with paracetamol**, Tablet 30 mg-500 mg
 5106R *BR* — **Glucose**, I.V. infusion 278 mmol (anhydrous) per L (5%), 1 L
 5164T *Momex SR 10, SI* — **Morphine sulfate**, Tablet 10 mg (controlled release)
 5165W *Momex SR 30, SI* — **Morphine sulfate**, Tablet 30 mg (controlled release)
 5166X *Momex SR 60, SI* — **Morphine sulfate**, Tablet 60 mg (controlled release)
 5167Y *Momex SR 100, SI* — **Morphine sulfate**, Tablet 100 mg (controlled release)
 5196L *APO-Paracetamol, TX* — **Paracetamol**, Tablet 500 mg
 5224Y *APO-Paracetamol, TX* — **Paracetamol**, Tablet 500 mg (**Diff. Max. Qty**)
 5212H *BR* — **Sodium chloride**, I.V. infusion 154 mmol per L (0.9%), 1 L
 5221T *APO-Temazepam, TX* — **Temazepam**, Tablet 10 mg

Additions — Bioequivalence Indicators

The bioequivalence indicator (a) has been added to the following brands:

- 5106R *BX* — **Glucose**, I.V. infusion 278 mmol (anhydrous) per L (5%), 1 L
 5212H *BX* — **Sodium chloride**, I.V. infusion 154 mmol per L (0.9%), 1 L

DELETIONS

Deletions — Brands

- 5196L *Parmol, SI* — **Paracetamol**, Tablet 500 mg
 5224Y *Parmol, SI* — **Paracetamol**, Tablet 500 mg (**Diff. Max. Qty**)

ALTERATIONS

Alterations — Manufacturer's Code

- | | | <i>From</i> | <i>To</i> |
|-------|--|-------------|-----------|
| 3313J | Ampicillin , Powder for injection 500 mg (<i>Ibimicyn</i>) | GM | TS |
| 3314K | Ampicillin , Powder for injection 1 g (<i>Ibimicyn</i>) | GM | TS |
| 5094D | Flucloxacillin , Powder for injection 500 mg (<i>Flubiclox</i>) | GM | TS |
| 5095E | Flucloxacillin , Powder for injection 1 g (<i>Flubiclox</i>) | GM | TS |

RETENTION OF BRANDS

Contrary to previous advice, the following brands will not be deleted from the Schedule of Pharmaceutical Benefits on 1 September 2009:

- 5196L *Dymadon P, PC* — **Paracetamol**, Tablet 500 mg
5224Y *Dymadon P, PC* — **Paracetamol**, Tablet 500 mg (**Diff. Max. Qty**)

Section 1 – Explanatory Notes

Introduction

These Explanatory Notes are provided to help dentists work within the Australian Government's Pharmaceutical Benefits Scheme (PBS).

The PBS is a system of subsidising the cost of most prescription medicines. The subsidies are available to all Australian residents and eligible foreign visitors, i.e., people from countries which have Reciprocal Health Care Agreements with Australia. These countries are the United Kingdom, Ireland, New Zealand, Malta, Italy, Sweden, the Netherlands, Finland, and Norway.

The aim of the PBS, which has been in operation since 1948, is to provide reliable and affordable access to a wide range of necessary medicines.

The Schedule of Pharmaceutical Benefits – referred to throughout as the 'Schedule' – lists all of the medicines available under the PBS, and explains how they can be used in order to be subsidised.

The Schedule is produced monthly by the Australian Department of Health and Ageing (effective on the first day of each month).

It is vital therefore that dentists remain up to date with information on which medicines are included in or excluded from the Schedule, whether restrictions apply to the medicines, and how much patients should pay. Queries relating to the PBS can be made to the Pharmaceutical Branch in the State offices of Medicare Australia (telephone 132 290 Mondays to Fridays, during business hours). Queries relating to the Repatriation Pharmaceutical Benefits Scheme (RPBS) can be made to the State offices of the Department of Veterans' Affairs (DVA) (telephone 1800 552 580).

1. The Schedule — Where to Find What

The Schedule of Pharmaceutical Benefits is divided into sections. At the start of the Schedule, immediately after the table of contents, is a summary of any changes to listed items.

The last pages of the Schedule provide a generic/proprietary index of PBS and RPBS ready-prepared items.

Section 1

Section 1 is what you are reading, the Explanatory Notes. It outlines the correct way to prescribe pharmaceutical benefits, patient charges and who qualifies for concessions. This is followed by a list of Medicare Australia contacts and addresses, then an index of manufacturers' codes.

Section 2

This section lists ready-prepared items, and includes the form, manner of administration, brand and brand equivalents that may be prescribed, and the maximum quantity for each item.

Any medicines that have restrictions on how they can be prescribed are printed in ***bold italics***. Items appearing in more than one therapeutic group are cross-referenced.

Page 2 of Section 2 explains symbols used throughout the Schedule.

The use of 'NOTE' in this section is used to clarify how some pharmaceutical benefits should be prescribed.

The use of 'CAUTION' is to warn of known adverse reactions from, or precautions to be taken with, a particular pharmaceutical benefit. (The absence of a cautionary note does not imply reactions may not happen.)

2. Prescribing Medicines — Information for Dentists

Eligible prescribers

Pharmaceutical benefits can only be prescribed by dentists who are approved to work within the PBS.

PBS prescription forms

Standard PBS prescription forms are available from Medicare Australia for prescribing pharmaceutical benefits.

- *Personalised forms* – have the dentist's name, qualifications, practice address/es, telephone number and prescriber number.
- *Non-personalised (blank) forms* – are distributed for emergency supply only. Both forms for dentists are supplied free of charge.

Ordering forms

Dentists are asked not to over order. Getting the right amount of forms helps to reduce the cost to taxpayers and helps to reduce paper wastage. Also, the pads may deteriorate if stored over time.

Order forms for standard PBS prescription forms are available from Medicare Australia stationery officers. Contact details are listed in the front of the Schedule.

Orders for PBS prescription stationery will only be accepted by application in writing and through the channels mentioned above.

Preparing general prescriptions

Do's and don't's

A PBS prescription is only valid when it is written by an approved dentist for dental treatment only.

The prescription must be for the treatment of the person named on the PBS prescription. A PBS prescription may only be written for the treatment of one person.

A dentist cannot write more than one PBS prescription for the same pharmaceutical benefit for the same person on the same day.

Up to **three** pharmaceutical benefit items may be included on a single PBS prescription form, but pharmaceutical benefits and non-pharmaceutical benefits should not be listed together on the one PBS prescription form.

If an item has a particular manner of administration it may not, as a pharmaceutical benefit, be administered in any other way, e.g., an ophthalmic preparation may not be prescribed for topical use.

If an item is restricted, but the patient is not suffering from one of the specified conditions, it cannot be prescribed as a pharmaceutical benefit. The dentist should write the prescription either on a private prescription or on a standard prescription with 'PBS/RPBS' clearly struck out. It should also be endorsed 'non-PBS'.

A dentist cannot prescribe a narcotic drug for him/herself. In some States and Territories the prescribing of drugs of addiction by dentists is not permitted.

Dentists are issued with individual PBS prescription pads by Medicare Australia for their own use – these pads should not be used by other dentists, as this can cause confusion through incorrect pharmacy records.

Dentists are required to include their prescriber numbers on non-personalised PBS prescriptions.

The following admixtures are not pharmaceutical benefits:

- the admixture of two or more ready-prepared items listed in the Schedule; or
- the admixture of a non-pharmaceutical benefit item with a pharmaceutical benefit item.

Writing the PBS prescription

The following rules apply for writing PBS prescriptions:

- they must be written in indelible form (i.e., ink or ball-point pen) in the dentist's own handwriting (exceptions must be approved by Medicare Australia's Chief Executive Officer) either on the standard PBS prescription, or on paper approximately 18 cm x 12 cm, or they can be generated by computer on a form approved by Medicare Australia. For patient safety reasons, both the original and the duplicate must be legible;
- they must record the dentist's name, address and prescriber number, the patient's name, address and entitlement status (i.e. whether they are a 'concessional' or 'general' patient), and whether the prescription is under the PBS or RPBS;
- they should completely identify the pharmaceutical benefit by detailing the item, dose, form, strength, quantity and instructions for use;
- they should indicate where brand substitution is not permitted. PBS prescriptions must not be prepared using a computer prescribing program that contains a default which would result in all prescriptions being indicated as Brand Substitution Not Permitted;
- where 'solvent required' is included after the form, the volume and number of ampoules must be specified; and
- they must be signed by the dentist and dated. Forward or back dating is not permitted.

There are separate arrangements for PBS prescriptions in certain public hospitals. To gain access to pharmaceutical benefits under this arrangement a patient must attend a participating public hospital and be a discharge patient or non-admitted patient. Only a dental practitioner providing dental services within a participating public hospital, may prescribe the subsidised medication. The States of Victoria, Queensland and Western Australia and the Northern Territory have agreed to implement these arrangements.

Restrictions

Pharmaceutical benefits listed in this Schedule fall into two broad categories:

Unrestricted benefits – which have no restrictions on their therapeutic uses; and

Restricted benefits – which can only be prescribed for specific therapeutic uses (they are noted as **restricted benefit**).

Maximum quantities

The maximum quantities allowed for PBS items are recommended by the Pharmaceutical Benefits Advisory Committee (PBAC). Dentists cannot prescribe repeats.

PBS prescriptions can be for any quantity up to the maximum. It is not necessary to prescribe the maximum quantity if a lesser quantity is sufficient for the patient's needs. Please clearly indicate the number of tablets, capsules, etc. required, and **do not use** abbreviations such as 'Max. Qty', or 'M.Q.'

Urgent cases

In urgent cases and where State/Territory law allows, a dentist may telephone a pharmacist and ask that a PBS prescription be supplied. He/she must then forward the written PBS prescription and duplicate to the pharmacist within **seven days of the date of supply**.

3. Patient Charges

Type of patient

There are two types of PBS beneficiaries – general patients and concessional patients. General patients hold a Medicare card. Concessional patients hold a Medicare card and one of the following cards from Centrelink or the Department of Veterans' Affairs (DVA):

- Pensioner Concession Card
- Commonwealth Seniors Health Card
- Health Care Card
- Repatriation Health Card For All Conditions (gold) – concessional patients under RPBS
- Repatriation Health Card For Specific Conditions (white) – only regarded as concessional patients for RPBS prescriptions unless they hold a separate entitlement from Centrelink, otherwise they are general patients
- Repatriation Pharmaceutical Benefits Card (orange) – concessional patients under RPBS
- Safety Net Concession Card or Safety Net Entitlement Card are also issued by Medicare Australia.

Under the Reciprocal Health Care Agreements (RHCA), visitors from participating countries (see the introduction of this section for the list of countries) are treated as general patients – they do not have concessional entitlements. To receive pharmaceutical benefits, these visitors may need to present a temporary Medicare card or their passport.

What patients pay

Patient contribution

Under the PBS, the maximum cost for a pharmaceutical benefit item at a pharmacy is \$32.90 for general patients and \$5.30 for concessional patients (except where a brand premium applies).

Patients who have a Safety Net Entitlement Card receive PBS items for free, except where a brand premium applies.

The contribution rate for general patients as outpatients at public hospitals throughout Australia is \$26.30.

The exception is Queensland and hospitals participating in the pharmaceutical reforms where they pay the safety net value of an item when it is listed in the Schedule, or up to \$32.90 for items not listed in the Schedule. The public hospital pharmaceutical reforms enable participating public hospitals to prescribe and supply pharmaceutical medication from the PBS to outpatients and patients upon discharge.

The contribution rate for concessional patients in all public hospitals is \$5.30.

The supply of a pharmaceutical benefit or a Repatriation pharmaceutical benefit to a patient is a GST-free supply. Goods and services tax must not be included in the price charged to a patient for the supply of a benefit under the PBS or RPBS.

It is the patient's responsibility to meet any charge lawfully demanded by an approved pharmacist, otherwise supply may be refused.

The patient contribution rates are usually adjusted on 1 January each year in line with inflation.

Patient contributions for early supply of some PBS medicines

Prescriptions for some pharmaceutical benefits are not eligible for Safety Net benefits if resupplied within 20 days of a previous supply of the same pharmaceutical benefit for the same person under the PBS or the RPBS. (This is known as the 'Safety Net 20 day rule' which came into effect on 1 January 2006.)

Where a prescription is subject to the Safety Net 20 day rule, exclusion from Safety Net benefits has the following effects:

- the patient contribution does not count towards the Safety Net
- after the Safety Net threshold is reached, the usual patient payment amount for the corresponding entitlement level (not the Safety Net amount) applies.

There are no pharmaceutical benefits listed for prescribing by dentists that are subject to the Safety Net 20 day rule.

Brand premiums

Under the brand premium arrangements, Commonwealth reimbursement to pharmacists is based on the lowest-priced brand. Patients pay the difference for higher-priced brands, on top of their usual patient contribution.

The Schedule's brand premiums apply to maximum quantities. When a quantity is less than the maximum, the premium will be a fraction of the maximum quantity, using standard pricing rules.

Solvents

Where a solvent is prescribed as part of a pharmaceutical benefit, only one patient contribution is charged.

4. RPBS Dental Prescribing

Under Department of Veterans' Affairs (DVA) arrangements, financial responsibility for pharmaceutical benefits prescribed by a Local Dental Officer (LDO) is limited to the treatment to which holders of the following cards are entitled:

- a Gold Repatriation Health Card For All Conditions; or
- a White Repatriation Health Card For Specific Conditions; or
- an Orange Repatriation Pharmaceutical Benefits Card.

Where possible the LDO shall prescribe in accordance with the provisions governing dental prescribing under the PBS.

Prescriptions for PBS Dental Schedule items for Gold, White and Orange Card holders are to be dispensed at the PBS concessional rate. The card holder is required to meet the cost of any applicable brand premium.

When a non-PBS Dental Schedule item is prescribed for an eligible card holder, the LDO's private prescription form should be used. The dispensing pharmacist may charge the patient the full cost of the prescription. The patient may claim a refund for the full cost of a non-Schedule item from DVA if an itemised receipt (not a cash register receipt) and a copy of the prescription are provided.

Addresses — Medicare Australia

Medicare Australia has responsibility for the operational aspects of the Pharmaceutical Benefits Scheme (PBS). This responsibility covers the processing of pharmaceutical benefit and safety net claims, and PBS stationery used by participating dental practitioners.

Procedures for ordering prescription forms are set out in Section 1 (Explanatory Notes) of this Schedule.

NEW SOUTH WALES and AUSTRALIAN CAPITAL TERRITORY

Pharmaceutical Benefits Branch

130 George Street
Parramatta NSW 2150

General and IME **Tel: 132 290**
enquiries—

Orange Service Centre
189 Anson Street
Orange NSW 2800

General and IME **Tel: 132 290**
enquiries—

VICTORIA

Pharmaceutical Branch

Level 10
595 Collins Street
Melbourne VIC 3000

General and IME **Tel: 132 290**
enquiries—

QUEENSLAND

Pharmaceutical Services Branch

143 Turbot Street
Brisbane QLD 4000

General and IME **Tel: 132 290**
enquiries—

SOUTH AUSTRALIA and NORTHERN TERRITORY

Pharmaceutical Services Branch

209 Greenhill Road
Eastwood SA 5063

General and IME **Tel: 132 290**
enquiries—

WESTERN AUSTRALIA

Pharmaceutical Benefits Branch

11th Floor, Bankwest Tower
108 St George's Terrace
Perth WA 6000

General and IME **Tel: 132 290**
enquiries—

TASMANIA

Pharmaceutical Branch

242 Liverpool Street
Hobart TAS 7000

General and IME **Tel: 132 290**
enquiries—

NATIONAL PROGRAM MANAGEMENT

Pharmaceutical Benefits Branch

Medicare Australia

134 Reed Street
Tuggeranong ACT 2900

Telephone— (02) 6124 6333

Website— www.medicareaustralia.gov.au

Email— pbs@medicareaustralia.gov.au

Index of Manufacturers' Codes

| <i>Code</i> | <i>Manufacturer</i> | <i>Code</i> | <i>Manufacturer</i> |
|-------------|--|-------------|---|
| AB | Abbott Australasia Pty Ltd Sir Joseph Banks Corporate Park 32-34 Lord Street Botany NSW 2019 Tel: (02) 9384 9700 Fax: (02) 9384 9800 | BF | Bellwether Pharma Limited Suite 2, Level 2 71 Epping Road North Ryde NSW 2113 Tel: (02) 8875 5700 Fax: (02) 9889 2250 |
| AF | Alphapharm Pty Limited Chase Building 2 Wentworth Park Road Glebe NSW 2037 Tel: (02) 9298 3999 Fax: (02) 9566 4686 | BQ | Bristol-Myers Squibb Pharmaceuticals A Division of Bristol-Myers Squibb Australia Pty Ltd 556 Princes Highway Noble Park Vic 3174 Tel: (03) 9213 4000 Fax: (03) 9701 1518 |
| AL | Alphapharm Medical A Division of Alphapharm Pty Limited Chase Building 2 Wentworth Park Road Glebe NSW 2037 Tel: (02) 9298 3999 Fax: (02) 9566 4686 | BR | B. Braun Australia Pty Ltd Norwest Business Park 17 Lexington Drive Bella Vista NSW 2153 Tel: (02) 9629 0200 Fax: (02) 9629 0299 |
| AP | AstraZeneca Pty Ltd Alma Road North Ryde NSW 2113 Tel: (02) 9978 3500 Fax: (02) 9978 3700 | BX | Baxter Healthcare Pty Limited 1 Baxter Drive Old Toongabbie NSW 2146 Tel: (02) 9848 1111 Fax: (02) 9848 1123 |
| AS | Aspen Pharmacare Australia Pty Ltd First Floor 34-36 Chandos Street St Leonards NSW 2065 Tel: (02) 8436 8300 Fax: (02) 9901 3540 | CH | Chem mart Pty Limited Level 7, 5 Queens Road Melbourne Vic 3004 Tel: (03) 9918 2500 Fax: (03) 9918 2006 |
| AV | Aventis Pharma Division of Sanofi-Aventis Australia Pty Limited Building D, Talavera Corporate Centre 12-24 Talavera Road Macquarie Park NSW 2113 Tel: (02) 8666 2000 Fax: (02) 8666 3000 | CO | Chemists' Own Pty Ltd A member of Sigma Group of Companies 96 Merrindale Drive Croydon Vic 3136 Tel: (03) 9839 2800 Fax: (03) 9839 2753 |
| AW | Arrow Pharmaceuticals Pty Ltd A member of Sigma Group of Companies 96 Merrindale Drive Croydon Vic 3136 Tel: (03) 9839 2800 Fax: (03) 9839 2753 | CR | Pharmacor Limited 5/36 Campbell Avenue Cromer NSW 2099 Tel: (02) 9981 4470 Fax: (02) 9981 4475 |
| | | CS | CSL Limited 45 Poplar Road Parkville Vic 3052 Tel: (03) 9389 1911 Fax: (03) 9388 2351 |

| <i>Code</i> | <i>Manufacturer</i> |
|-------------|--|
| DT | DermaTech Laboratories Pty Ltd Unit 17, 167 Prospect Highway Seven Hills NSW 2147 Tel: (02) 9624 5874 Fax: (02) 9624 8822 |
| FA | F.H. Faulding & Co. Limited Level 6, 390 St Kilda Road Melbourne Vic 3004 Tel: (03) 9868 0700 Fax: (03) 9868 0111 |
| FK | PharmaLink Pty Ltd Level 8, 67 Albert Avenue Chatswood NSW 2067 Tel: (02) 9080 7200 Fax: (02) 9080 7201 |
| FM | Fawns and McAllan Pty Ltd A member of Sigma Group of Companies 96 Merrindale Drive Croydon Vic 3136 Tel: (03) 9839 2800 Fax: (03) 9839 2753 |
| GK | GlaxoSmithKline Australia Pty Ltd 1061 Mountain Highway Boronia Vic 3155 Tel: (03) 9721 6000 Fax: (03) 9729 5319 |
| GM | Genepharm Pty Ltd 3/10 Inglewood Place Norwest Business Park Baulkham Hills NSW 2153 Tel: 1800 678 302 Fax: (02) 8818 2122 |
| GN | Genepharm Australasia Limited Level 1, 263 City Road Southbank Vic 3006 Tel: 1800 508 168 Fax: (03) 9699 8333 |
| GX | GenRx A Division of Apotex Pty Ltd 66 Waterloo Road North Ryde NSW 2113 Tel: (02) 8877 8333 Fax: (02) 8877 8377 |

| <i>Code</i> | <i>Manufacturer</i> |
|-------------|---|
| HH | Hospira Pty Ltd (David Bull Laboratories, Faulding Pharmaceuticals) Level 6, 390 St Kilda Road Melbourne Vic 3004 Tel: (03) 9868 0700 Fax: (03) 9868 0111 |
| HX | Hexal Australia A division of Sandoz Pty Ltd Level 4, Suite 7-19 100 Harris Street Pymont NSW 2009 Tel: (02) 9566 1500 Fax: (02) 9566 1458 |
| IA | iNova Pharmaceuticals (Australia) Pty Limited 9-15 Chilvers Road Thornleigh NSW 2120 Tel: (02) 9875 6333 Fax: (02) 9875 6416 |
| JC | Janssen-Cilag Pty Ltd 1-5 Khartoum Road North Ryde NSW 2113 Tel: (02) 8875 3333 Fax: (02) 8875 3300 |
| KR | Kenral Division of Pharmacia Australia Pty Limited 59 Kirby Street Rydalmere NSW 2116 Tel: (02) 9848 3000 Fax: (02) 9848 3333 |
| LM | Link Medical Products Pty Ltd Level 1, Bridgepoint Centre 3 Brady Street Mosman NSW 2088 Tel: (02) 9960 0150 Fax: (02) 9960 0149 |
| LN | Lennon Healthcare A Division of Aspen Pharmacare Australia Pty Ltd First Floor 34-36 Chandos Street St Leonards NSW 2065 Tel: (02) 8436 8300 Fax: (02) 9901 3540 |

| <i>Code</i> | <i>Manufacturer</i> |
|-------------|---|
| MD | Macarthur Research Division of Roche Products Pty Ltd 4-10 Inman Road Dee Why NSW 2099 Tel: (02) 9454 9000 Fax: (02) 9981 3229 |
| MF | Mundipharma Pty Ltd Level 33, 50 Bridge Street Sydney NSW 2000 Tel: (02) 9231 7200 Fax: (02) 9223 0011 |
| MI | Meditech Int. Pty Ltd Unit 5, 36 Campbell Avenue Cromer NSW 2099 Tel: (02) 9981 4470 Fax: (02) 9981 4475 |
| NO | Novo Nordisk Pharmaceuticals Pty Ltd Level 3, 21 Solent Circuit Baulkham Hills NSW 2153 Tel: (02) 8858 3600 Fax: (02) 8858 3799 |
| NV | Novartis Pharmaceuticals Australia Pty Ltd 54 Waterloo Road North Ryde NSW 2113 Tel: (02) 9805 3555 Fax: (02) 9887 4551 |
| PC | Pfizer Consumer Healthcare Pty Ltd 32 Cawarra Road Caringbah NSW 2229 Tel: (02) 9710 6500 Fax: (02) 9710 6644 |
| PF | Pfizer Pty Limited 38-42 Wharf Road West Ryde NSW 2114 Tel: (02) 9850 3333 Fax: (02) 9858 1347 |
| PH | Pharmacia Australia Pty Limited 38-42 Wharf Road West Ryde NSW 2114 Tel: (02) 9850 3333 Fax: (02) 9858 1347 |

| <i>Code</i> | <i>Manufacturer</i> |
|-------------|--|
| PK | Pharmatel Fresenius Kabi Pty Ltd Unit 6, 6-18 Bridge Road Hornsby NSW 2077 Tel: (02) 9472 2222 Fax: (02) 9472 2255 |
| PL | Phebra 332 Burns Bay Road Lane Cove NSW 2066 Tel: (02) 9420 9199 Fax: (02) 9420 9177 |
| RA | Ranbaxy Australia Pty Limited Suite 4.02, Level 4 Building D 12-24 Talavera Road North Ryde NSW 2113 Tel: (02) 9647 1172 Fax: (02) 9647 1172 |
| RC | Reckitt Benckiser (Australia) Pty Limited 44 Wharf Road West Ryde NSW 2114 Tel: (02) 9857 2000 Fax: (02) 9857 2004 |
| RO | Roche Products Pty Ltd 4-10 Inman Road Dee Why NSW 2099 Tel: (02) 9454 9000 Fax: (02) 9971 7401 |
| SH | Schering-Plough Pty Ltd Level 4, 66 Waterloo Road North Ryde NSW 2113 Tel: (02) 8988 8000 Fax: (02) 9852 7500 |
| SI | Sigma Pharmaceuticals (Australia) Pty Ltd A member of Sigma Group of Companies 96 Merrindale Drive Croydon Vic 3136 Tel: (03) 9839 2800 Fax: (03) 9839 2753 |
| SU | Sauter Laboratories (Aust.) Pty Ltd 4-10 Inman Road Dee Why NSW 2099 Tel: (02) 9454 9000 Fax: (02) 9981 3229 |

| <i>Code</i> | <i>Manufacturer</i> |
|-------------|---------------------|
|-------------|---------------------|

SW Sanofi-Aventis Australia Pty Ltd
Building D, Talavera Corporate Centre
12-24 Talavera Road Macquarie Park NSW
2113
Tel: (02) 8666 2000
Fax: (02) 8666 3000

SZ Sandoz Pty Ltd
Level 4, Suite 7-19
100 Harris Street Pyrmont NSW 2009
Tel: (02) 9566 1500
Fax: (02) 9566 1458

TS Specialised Therapeutics Australia Pty
Ltd
Suite 3-4, 6 Westbrook Street
East Kew Vic 3102
Tel: (03) 9859 1493
Fax: (03) 9859 6950

TW Terry White Chemists
Level 7, 5 Queens Road
Melbourne Vic 3004
Tel: (03) 9918 2500
Fax: (03) 9918 2006

TX Apotex Pty Ltd
66 Waterloo Road
North Ryde NSW 2113
Tel: (02) 8877 8333
Fax: (02) 8877 8377

VT Valeant Pharmaceuticals Australasia
Pty Ltd
Level 1, 85 St Hilliers Road
Auburn NSW 2144
Tel: (02) 9648 4266
Fax: (02) 9648 4655

XF Max Pharma
Suite 2, 210 Whitehorse Road
Balwyn Vic 3103
Tel: (03) 9888 5222
Fax: (03) 9888 5288

YM Symbion Pharmacy Services Pty Ltd
Level 7, 5 Queens Road
Melbourne Vic 3004
Tel: (03) 9918 2000
Fax: (03) 9918 2006

| <i>Code</i> | <i>Manufacturer</i> |
|-------------|---------------------|
|-------------|---------------------|

THERAPEUTIC INDEX

THERAPEUTIC INDEX

ALIMENTARY TRACT AND METABOLISM 25

STOMATOLOGICAL PREPARATIONS 25

Stomatological preparations 25

DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 25

Belladonna and derivatives, plain 25

Propulsives 25

ANTIEMETICS AND ANTINAUSEANTS 25

Antiemetics and antinauseants 25

ANTIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ ANTIINFECTIVE AGENTS 26

Intestinal antiinfectives 26

BLOOD AND BLOOD FORMING ORGANS 27

BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS 27

I.V. solutions 27

CARDIOVASCULAR SYSTEM 28

CARDIAC THERAPY 28

Antiarrhythmics, class I and III 28

Cardiac stimulants excl. cardiac glycosides 28

Vasodilators used in cardiac diseases 28

DERMATOLOGICALS 29

CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 29

Corticosteroids, plain 29

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS 30

CORTICOSTEROIDS FOR SYSTEMIC USE 30

Corticosteroids for systemic use, plain 30

PANCREATIC HORMONES 30

Glycogenolytic hormones 30

ANTIINFECTIVES FOR SYSTEMIC USE 31

ANTIBACTERIALS FOR SYSTEMIC USE 31

Tetracyclines 31

Beta-lactam antibacterials, penicillins 31

Other beta-lactam antibacterials 35

Sulfonamides and trimethoprim 38

Macrolides, lincosamides and streptogramins 38

Other antibacterials 39

MUSCULO-SKELETAL SYSTEM 41

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 41

Antiinflammatory and antirheumatic products, non-steroids 41

NERVOUS SYSTEM 44

ANALGESICS 44

Opioids 44

Other analgesics and antipyretics 49

ANTIEPILEPTICS 50

Antiepileptics 50

ANTI-PARKINSON DRUGS 50

Anticholinergic agents 50

PSYCHOLEPTICS 51

Anxiolytics 51

Hypnotics and sedatives 51

RESPIRATORY SYSTEM 52

DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 52

Adrenergics for systemic use 52

SENSORY ORGANS 53

OPHTHALMOLOGICALS 53

Antiinfectives 53

VARIOUS 54

ALL OTHER THERAPEUTIC PRODUCTS 54

All other therapeutic products 54

ALL OTHER NON-THERAPEUTIC PRODUCTS 54

THERAPEUTIC INDEX

All other non-therapeutic products 54

Section 2
Schedule of Benefits

SYMBOLS USED IN THE SCHEDULE

An arrow (>) in front of a restriction indicates an additional or amended purpose in this issue.

An asterisk (*) against the dispensed price of a benefit indicates that the manufacturer's pack does not coincide with the maximum quantity.

A double dagger (†) in the maximum quantity column indicates an item for which the maximum quantity has been specially determined to correspond to the manufacturer's pack and the manufacturer's standard pack should be prescribed and supplied. For any item where a maximum quantity greater than 1 is marked with a double dagger (†), that maximum quantity should be prescribed and supplied.

A gauge sign (#) against the dispensed price of a benefit indicates that the product is not preconstituted and that an extemporaneously-prepared dispensing fee is included in the dispensed price and, where appropriate, an amount for purified water.

Where a STATE is indicated after a manufacturer's code, that brand may be available only in the State indicated. NSW-(N); Vic-(V); Qld-(Q); SA-(S); WA-(W); Tas-(T).

RESTRICTED BENEFITS

All restricted items are printed in ***bold italics***. These items may be prescribed as pharmaceutical benefits only for use for one of the specified indications. Where more than one indication is specified for a restricted pharmaceutical benefit, each indication is separated from the preceding indication by a semi-colon and commences on the next line. The drug may be prescribed as a pharmaceutical benefit for a patient who qualifies under any of the specified indications.

A straight line is drawn between entries for different forms and strengths of an item to indicate clearly the different restrictions which apply to these various forms and strengths.

CODES FOR INJECTABLE ITEMS WITH ALLOWABLE SOLVENTS

The entry in this Schedule of those pharmaceutical benefit injectable items which require a solvent includes the codes of the items with the relevant solvents. For each such item the code is for the injectable with 10 mL sodium chloride injection 9 mg per mL (0.9%).

BRAND EQUIVALENCE

'a' located immediately before brand names of a particular strength of an item indicates that the sponsors of these brands have submitted evidence that they have been demonstrated to be bioequivalent or therapeutically equivalent, or that justification for not needing bioequivalence or therapeutic equivalence data has been provided to and accepted by the Therapeutic Goods Administration. It would thus be expected that these brands may be interchanged without differences in clinical effect.

For other brands of an item, i.e., those not indicated as above, it is unknown whether or not they are equivalent. There may be several reasons for this, such as bioequivalence data not being considered necessary when the products were approved for marketing, or that advice or data have not been forthcoming from sponsors. This does not necessarily suggest a lack of safety or efficacy, but in these circumstances caution should be taken if brands are interchanged.

'b' attached to brand names indicates that these brands are also equivalent, but that it is not known if there is equivalence between brands marked 'a' and brands marked 'b'.

BRAND PREMIUM POLICY

The Brand Premium Policy was introduced on 1 December 1990 to increase price competition by allowing pharmaceutical manufacturers to set their own price on multi-branded items listed on the Pharmaceutical Benefits Scheme and to encourage the development of the generic pharmaceutical industry in Australia.

The policy does this by increasing prescribers' and patients' consciousness about the price of drugs. In effect, it makes both groups question whether it is necessary for the patient to pay more for the drugs when a cheaper brand is available. The policy also allows companies to establish prices taking into account competition and consumer acceptance.

The policy operates where there is more than one brand of a particular drug available through the Pharmaceutical Benefits Scheme and where the brands are therapeutically interchangeable. Due to this, the policy mainly applies to out of patent drugs.

Basically the policy operates by:

- the Australian Government subsidising a drug to the level of the lowest priced brand (except in those instances where the lowest priced brand has, as part of its price, a therapeutic group premium);
- suppliers of other brands of that drug being able to set a price above the price charged by the supplier(s) of the lowest priced brand(s); and
- the patient paying the brand premium which is the price difference between the lowest price brand and the brand prescribed.

If a prescription is written generically or for the lowest priced brand, and the lowest priced brand is supplied, there is no brand premium payable.

'B' located immediately before an amount in the premium column indicates a brand premium which applies to that particular brand of the item.

The success of the Government in controlling prices of products supplied through the Pharmaceutical Benefits Scheme has often been criticised by the pharmaceutical industry. Under the Brand Premium Policy, suppliers of multi-branded items are able to set their own prices at a level that they think the market will bear. At the same time, the prescriber and the patient can decide whether it is necessary to pay more for a particular brand when a cheaper one is available and is therapeutically interchangeable.

The brand premium does not count toward the patient's safety net.

It should be noted that the brand premium is not a Government charge or revenue. The premium arises from the manufacturer's price and the majority goes to the manufacturer with wholesalers and pharmacists receiving a small percentage.

SPECIAL PHARMACEUTICAL BENEFITS

The special patient contribution is payable by all patients in addition to the relevant patient contribution for concessional and general patients.

| Code | Name, Restriction, Manner of Administration and form | Max. Qty | No. of Rpts | Premium | Reimburse- ment Price for Max. Qty \$ | Total Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer |
|------|--|----------|----------------|---------|--|---|--|--------------------------------------|
|------|--|----------|----------------|---------|--|---|--|--------------------------------------|

| |
|---|
| PHARMACEUTICAL BENEFITS FOR DENTAL USE |
|---|

AMOXYCILLIN

| | | | | | | | | | |
|-------|--|-----|----|-------|---------|---------|-------|--------|----|
| 3310F | Powder for paediatric oral drops 100 mg per mL, 20 mL | ‡ 1 | .. | s0.61 | # 13.17 | # 13.78 | 14.55 | Amoxil | GK |
|-------|--|-----|----|-------|---------|---------|-------|--------|----|

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|------|---|-------------|----------------|---------|--|--|--------------------------------------|--|
|------|---|-------------|----------------|---------|--|--|--------------------------------------|--|

ALIMENTARY TRACT AND METABOLISM

STOMATOLOGICAL PREPARATIONS

Stomatological preparations

- **Antiinfectives and antiseptics for local oral treatment**

AMPHOTERICIN

| | | | | | | | | |
|-------|---------------|----|----|----|-------|-------|----------|----|
| 3306B | Lozenge 10 mg | 20 | .. | .. | 11.34 | 12.39 | Fungilin | BQ |
|-------|---------------|----|----|----|-------|-------|----------|----|

NYSTATIN

| | | | | | | | | |
|-------|--|-----|----|----|-------|-------|-----------------------|----------|
| 3343Y | Oral suspension 100,000 units per mL, 24 mL | ‡ 1 | .. | .. | 10.85 | 11.90 | Mycostatin Nilstat | BQ SI |
|-------|--|-----|----|----|-------|-------|-----------------------|----------|

- **Other agents for local oral treatment**

BENZYDAMINE HYDROCHLORIDE

Restricted Benefit

Radiation induced mucositis.

| | | | | | | | | |
|-------|---|-----|----|----|-------|-------|---------|----|
| 5032W | Mouth and throat rinse 22.5 mg per 15 mL, 500 mL | ‡ 1 | .. | .. | 22.26 | 23.31 | Difflam | IA |
|-------|---|-----|----|----|-------|-------|---------|----|

DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

Belladonna and derivatives, plain

- **Belladonna alkaloids, tertiary amines**

ATROPINE SULFATE

| | | | | | | | | |
|-------|----------------------------------|----|----|----|-------|-------|----|--|
| 5022H | Injection 600 micrograms in 1 mL | 10 | .. | .. | 20.54 | 21.59 | AP | |
|-------|----------------------------------|----|----|----|-------|-------|----|--|

Propulsives

- **Propulsives**

METOCLOPRAMIDE HYDROCHLORIDE

| | | | | | | | | |
|-------|--------------|----|----|----|------|------|--------|----|
| 5151D | Tablet 10 mg | 25 | .. | .. | 8.20 | 9.25 | Pramin | AF |
|-------|--------------|----|----|----|------|------|--------|----|

| | | | | | | | | | |
|--|--|--|--|--|-------|-------|------|---------|----|
| | | | | | B3.02 | 11.22 | 9.25 | Maxolon | VT |
|--|--|--|--|--|-------|-------|------|---------|----|

| | | | | | | | | |
|-------|-------------------------|----|----|----|-------|-------|---------|----|
| 5153F | Injection 10 mg in 2 mL | 10 | .. | .. | 12.99 | 14.04 | Maxolon | VT |
|-------|-------------------------|----|----|----|-------|-------|---------|----|

ANTIEMETICS AND ANTINAUSEANTS

Antiemetics and antinauseants

- **Other antiemetics**

PROCHLORPERAZINE

CAUTION:

Prochlorperazine may be associated with parkinsonism and tardive dyskinesia and should be used for short-term treatment only.

| | | | | | | | | |
|-------|--|----|----|----|------|-------|------------------------|----|
| 5205Y | Tablet containing prochlorperazine maleate 5 mg | 25 | .. | .. | 9.95 | 11.00 | ^a Stemizine | AV |
|-------|--|----|----|----|------|-------|------------------------|----|

| | | | | | | | | | |
|--|--|--|--|--|-------|-------|-------|-----------------------|----|
| | | | | | B2.44 | 12.39 | 11.00 | ^a Stemetil | SW |
|--|--|--|--|--|-------|-------|-------|-----------------------|----|

| | | | | | | | | |
|-------|---|----|----|----|-------|-------|----------|----|
| 5206B | Injection containing prochlorperazine mesylate 12.5 mg in 1 mL | 10 | .. | .. | 16.82 | 17.87 | Stemetil | SW |
|-------|---|----|----|----|-------|-------|----------|----|

continued ↪

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|-------|---|-------------|----------------|---------|--|--|--------------------------------------|----|
| 5208D | Suppositories containing prochlorperazine equivalent to 25 mg prochlorperazine maleate, 5 | ‡ 1 | .. | .. | 19.93 | 20.98 | Stemetil | SW |
| | PROMETHAZINE HYDROCHLORIDE | | | | | | | |
| 3374N | Injection 50 mg in 2 mL | 10 | .. | .. | * 22.32 | 23.37 | HH | |

| |
|---|
| ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ ANTIINFECTIVE AGENTS |
|---|

Intestinal antiinfectives
• Antibiotics

NYSTATIN

| | | | | | | | | |
|-------|-----------------------|----|----|----|-------|-------|---------|----|
| 3342X | Tablet 500,000 units | 50 | .. | .. | 17.98 | 19.03 | Nilstat | SI |
| 3345C | Capsule 500,000 units | 50 | .. | .. | 17.98 | 19.03 | Nilstat | SI |

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer |
|------|---|-------------|----------------|---------|--|--|--------------------------------------|
|------|---|-------------|----------------|---------|--|--|--------------------------------------|

BLOOD AND BLOOD FORMING ORGANS

BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS

I.V. solutions

• *Solutions for parenteral nutrition*

GLUCOSE

| | | | | | | | |
|-------|--|---|----|----|---------|-------|------------------------------------|
| 5005K | I.V. infusion 139 mmol (anhydrous) per 500 mL (5%), 500 mL | 5 | .. | .. | * 18.32 | 19.37 | ^a BR ^a PK |
| 5106R | I.V. infusion 278 mmol (anhydrous) per L (5%), 1 L | 5 | .. | .. | * 23.52 | 24.57 | ^a BX ^a BR |

• *Solutions affecting the electrolyte balance*

SODIUM CHLORIDE

| | | | | | | | |
|-------|---|---|----|----|---------|-------|------------------------------------|
| 5021G | I.V. infusion 77 mmol per 500 mL (0.9%), 500 mL | 5 | .. | .. | * 18.32 | 19.37 | ^a BR ^a PK |
| 5212H | I.V. infusion 154 mmol per L (0.9%), 1 L | 5 | .. | .. | * 23.52 | 24.57 | ^a BX ^a BR |
| 5213J | I.V. infusion 513 mmol per L (3%), 1 L | 2 | .. | .. | * 16.74 | 17.79 | BX |

SODIUM CHLORIDE with GLUCOSE

| | | | | | | | |
|-------|--|---|----|----|---------|-------|----|
| 5214K | I.V. infusion 31 mmol-222 mmol (anhydrous) per L (0.18%-4%), 1 L | 5 | .. | .. | * 23.52 | 24.57 | BX |
| 5215L | I.V. infusion 19 mmol-104 mmol (anhydrous) per 500 mL (0.225%-3.75%), 500 mL | 5 | .. | .. | * 28.77 | 29.82 | BX |
| 5216M | I.V. infusion 39 mmol-69 mmol (anhydrous) per 500 mL (0.45%-2.5%), 500 mL | 5 | .. | .. | * 28.77 | 29.82 | BX |

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer |
|------|---|-------------|----------------|---------|--|--|--------------------------------------|
|------|---|-------------|----------------|---------|--|--|--------------------------------------|

DERMATOLOGICALS

CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS

Corticosteroids, plain

• Corticosteroids, weak (group I)

HYDROCORTISONE ACETATE

Restricted Benefit

Treatment of corticosteroid-responsive dermatoses.

| | | | | | | | | | |
|-------|---|-----|----|-------|-------|-------|---------------------------|------------------------|----|
| 5111B | Cream 10 mg per g (1%), 30 g | ‡ I | .. | .. | 8.98 | 10.03 | ^a Cortic-DS 1% | FM | |
| | | | | B1.87 | 10.85 | 10.03 | | ^a Sigmacort | SI |
| 5113D | Cream 10 mg per g (1%), 50 g | ‡ I | .. | .. | 8.65 | 9.70 | ^a Cortic-DS 1% | FM | |
| | | | | B0.08 | 8.73 | 9.70 | | Cortef | DT |
| | | | | B1.88 | 10.53 | 9.70 | | ^a Sigmacort | SI |
| 5112C | Topical ointment 10 mg per g (1%), 30 g | ‡ I | .. | .. | 8.98 | 10.03 | ^a Cortic-DS 1% | FM | |
| | | | | B1.87 | 10.85 | 10.03 | | ^a Sigmacort | SI |
| 5114E | Topical ointment 10 mg per g (1%), 50 g | ‡ I | .. | .. | 8.65 | 9.70 | ^a Cortic-DS 1% | FM | |
| | | | | B1.88 | 10.53 | 9.70 | | ^a Sigmacort | SI |

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|------|---|-------------|----------------|---------|--|--|--------------------------------------|--|
|------|---|-------------|----------------|---------|--|--|--------------------------------------|--|

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

CORTICOSTEROIDS FOR SYSTEMIC USE

Corticosteroids for systemic use, plain

• Glucocorticoids

**BETAMETHASONE ACETATE with BETAMETHASONE
SODIUM PHOSPHATE**

Restricted Benefit

For local intra-articular or peri-articular infiltration;

Keloid;

Lichen planus hypertrophic.

| | | | | | | | | |
|-------|---|---|----|----|-------|-------|-------------------------|----|
| 5034Y | Injection 3 mg-3.9 mg (equivalent to 5.7 mg betamethasone) in 1 mL | 5 | .. | .. | 25.77 | 26.82 | Celestone Chronodose | SH |
|-------|---|---|----|----|-------|-------|-------------------------|----|

HYDROCORTISONE SODIUM SUCCINATE

Restricted Benefit

For use in a hospital.

| | | | | | | | | |
|-------|--|---|----|----|---------|-------|-------------|----|
| 5118J | Injection equivalent to 100 mg hydrocortisone with 2 mL solvent | 6 | .. | .. | * 37.98 | 32.90 | Solu-Cortef | PH |
|-------|--|---|----|----|---------|-------|-------------|----|

| | | | | | | | | |
|-------|--|---|----|----|---------|-------|-------------|----|
| 5119K | Injection equivalent to 250 mg hydrocortisone with 2 mL solvent | 6 | .. | .. | * 60.96 | 32.90 | Solu-Cortef | PH |
|-------|--|---|----|----|---------|-------|-------------|----|

METHYLPREDNISOLONE ACETATE

Restricted Benefit

For local intra-articular or peri-articular infiltration.

| | | | | | | | | |
|-------|-------------------------|---|----|-------|-------|-------|----------------------------|----|
| 5148Y | Injection 40 mg in 1 mL | 5 | .. | .. | 24.97 | 26.02 | ^a Depo-Nisolone | KR |
| | | | | b0.75 | 25.72 | 26.02 | ^a Depo-Medrol | PH |

TRIAMCINOLONE ACETONIDE

Restricted Benefit

For local intra-articular or peri-articular infiltration;

Keloid;

Lichen planus hypertrophic.

| | | | | | | | | |
|-------|-------------------------|---|----|----|-------|-------|--------------|----|
| 5233K | Injection 10 mg in 1 mL | 5 | .. | .. | 25.77 | 26.82 | Kenacort-A10 | BQ |
|-------|-------------------------|---|----|----|-------|-------|--------------|----|

PANCREATIC HORMONES

Glycogenolytic hormones

• Glycogenolytic hormones

GLUCAGON HYDROCHLORIDE

| | | | | | | | | |
|-------|--|---|----|----|-------|-------|------------------|----|
| 5105Q | Injection set containing 1 mg (1 i.u.) and 1 mL solvent in disposable syringe | 1 | .. | .. | 45.63 | 32.90 | GlucaGen Hypokit | NO |
|-------|--|---|----|----|-------|-------|------------------|----|

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|---|---|-------------|----------------|---------|--|--|--|----------|
| ANTIINFECTIVES FOR SYSTEMIC USE | | | | | | | | |
| ANTIBACTERIALS FOR SYSTEMIC USE | | | | | | | | |
| Tetracyclines | | | | | | | | |
| • Tetracyclines | | | | | | | | |
| DOXYCYCLINE | | | | | | | | |
| 5082L | Tablet 100 mg (as monohydrate) | 7 | .. | .. | 8.47 | 9.52 | a Chem mart Doxycycline | CH |
| | | | | | | | a Doxyhexal | SZ |
| | | | | | | | a GenRx Doxycycline | GX |
| | | | | | | | a Terry White Chemists Doxycycline | TW |
| 3321T | Tablet 100 mg (as hydrochloride) | 7 | .. | .. | 8.47 | 9.52 | a Doxsig a Doxy-100 | SI GM |
| | | | | | | | a Doxylin 100 | AF |
| | | | | B1.19 | 9.66 | 9.52 | a Vibramycin | PF |
| NOTE: | | | | | | | | |
| Bioequivalence has been demonstrated between doxycycline tablet 100 mg (as hydrochloride) and doxycycline tablet 100 mg (as monohydrate). | | | | | | | | |
| 3322W | Capsule 100 mg (as hydrochloride) | 7 | .. | .. | 8.47 | 9.52 | a DBL Doxycycline | FA |
| | | | | B1.15 | 9.62 | 9.52 | a Doryx | HH |
| Beta-lactam antibacterials, penicillins | | | | | | | | |
| • Penicillins with extended spectrum | | | | | | | | |
| AMOXYCILLIN | | | | | | | | |
| 3301R | Capsule 250 mg | 20 | .. | .. | 8.55 | 9.60 | a Alphamox 250 | AF |
| | | | | | | | a Amohexal | HX |
| | | | | | | | a Amoxycillin-DP | GM |
| | | | | | | | a Amoxycillin Ranbaxy | RA |
| | | | | | | | a Amoxycillin Sandoz | SZ |
| | | | | | | | a APO-Amoxycillin | TX |
| | | | | | | | a Chem mart Amoxycillin | CH |
| | | | | | | | a Cilamox | SI |
| | | | | | | | a GenRx Amoxycillin | GX |
| | | | | | | | a Terry White Chemists Amoxycillin | TW |
| | | | | B0.79 | 9.34 | 9.60 | a Amoxil | GK |

continued ↗

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|-------|---|-------------|----------------|---------|--|--|--------------------------------------|----|
| 3300Q | Capsule 500 mg | 20 | .. | .. | 10.65 | 11.70 | a Alphamox 500 | AF |
| | | | | | | | a Amoxicillin-DP | GM |
| | | | | | | | a Amoxicillin | RA |
| | | | | | | | Ranbaxy | |
| | | | | | | | a Amoxicillin | SZ |
| | | | | | | | Sandoz | |
| | | | | | | | a APO-Amoxicillin | TX |
| | | | | | | | a Chem mart | CH |
| | | | | | | | Amoxicillin | |
| | | | | | | | a Cilamox | SI |
| | | | | | | | a GenRx | GX |
| | | | | | | | Amoxicillin | |
| | | | | | | | a Moxacin | AS |
| | | | | | | | a Terry White | TW |
| | | | | | | | Chemists | |
| | | | | | | | Amoxicillin | |
| | | | | b0.80 | 11.45 | 11.70 | a Amoxil | GK |
| 3309E | Sachet containing oral powder 3 g | 1 | .. | .. | 9.11 | 10.16 | Amoxil | GK |
| 3302T | Powder for syrup 125 mg per 5 mL, 100 mL | ‡ 1 | .. | .. | # 10.84 | 12.22 | a Alphamox 125 | AF |
| | | | | | | | a Amoxicillin | SZ |
| | | | | | | | Sandoz | |
| | | | | | | | a Bgramin | GM |
| | | | | | | | a Chem mart | CH |
| | | | | | | | Amoxicillin | |
| | | | | | | | a GenRx | GX |
| | | | | | | | Amoxicillin | |
| | | | | | | | a Ranmoxy | RA |
| | | | | | | | a Terry White | TW |
| | | | | | | | Chemists | |
| | | | | | | | Amoxicillin | |
| | | | | b0.95 | # 11.79 | 12.22 | a Amoxil | GK |
| 3393N | Powder for syrup 250 mg per 5 mL, 100 mL | ‡ 1 | .. | .. | # 11.68 | 13.06 | a Alphamox 250 | AF |
| | | | | | | | a Amoxicillin | SZ |
| | | | | | | | Sandoz | |
| | | | | | | | a Bgramin | GM |
| | | | | | | | a Chem mart | CH |
| | | | | | | | Amoxicillin | |
| | | | | | | | a Cilamox | SI |
| | | | | | | | a GenRx | GX |
| | | | | | | | Amoxicillin | |
| | | | | | | | a Ranmoxy | RA |
| | | | | | | | a Terry White | TW |
| | | | | | | | Chemists | |
| | | | | | | | Amoxicillin | |
| | | | | b0.79 | # 12.47 | 13.06 | a Amoxil Forte | GK |
| 5225B | Powder for oral suspension 500 mg per 5 mL, 100 mL | ‡ 1 | .. | .. | # 14.69 | 16.07 | Maxamox | SZ |

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|---|---|-------------|----------------|---------|--|--|---|----------------|
| AMPICILLIN | | | | | | | | |
| 3313J | Powder for injection 500 mg | 5 | .. | .. | 11.08 | 12.13 | ^a Austrapen ^a Ibimicycyn | LN TS |
| 3314K | Powder for injection 1 g | 5 | .. | .. | 14.07 | 15.12 | ^a Aspen Ampicyn ^a Austrapen ^a Ibimicycyn | AS LN TS |
| • Beta-lactamase sensitive penicillins | | | | | | | | |
| BENZATHINE BENZYL PENICILLIN | | | | | | | | |
| 5027N | Injection 900 mg in 2.3 mL single use pre-filled syringe | 10 | .. | .. | 293.11 | 32.90 | Bicillin L-A | AS |
| BENZYL PENICILLIN | | | | | | | | |
| 3398W | Powder for injection 600 mg | 10 | .. | .. | * 42.92 | 32.90 | BenPen | CS |
| 3399X | Powder for injection 3 g | 10 | .. | .. | * 66.92 | 32.90 | BenPen | CS |
| PHENOXYMETHYL PENICILLIN | | | | | | | | |
| 3360W | Tablet 250 mg | 50 | .. | .. | * 11.58 | 12.63 | Abbecillin-VK Filmstab | SI |
| 3361X | Tablet 500 mg | 50 | .. | .. | * 14.06 | 15.11 | Abbecillin-VK Filmstab | SI |
| 3363B | Capsule 250 mg | 50 | .. | .. | 11.41 11.41 | 12.46 12.46 | LPV ^a Cilicaïne VK ^a Cilopen VK | AS FM GM |
| 3364C | Capsule 500 mg | 50 | .. | .. | 13.84 13.84 | 14.89 14.89 | LPV ^a Cilicaïne VK ^a Cilopen VK | AS FM GM |
| 5012T | Oral suspension 150 mg (as benzathine) per 5 mL, 100 mL | 2 | .. | .. | * 22.40 | 23.45 | Abbecillin-V Cilicaïne V | SI FM |
| PROCAINE PENICILLIN | | | | | | | | |
| 3371K | Injection 1.5 g | 5 | .. | .. | 92.22 | 32.90 | Cilicaïne | SI |
| • Beta-lactamase resistant penicillins | | | | | | | | |
| DICLOXACILLIN | | | | | | | | |
| <u>Restricted Benefit</u> | | | | | | | | |
| <i>Serious staphylococcal infections.</i> | | | | | | | | |
| 5096F | Capsule 250 mg | 24 | .. | .. | 11.45 | 12.50 | ^a Diclocil ^a Dicloxsig ^a Distaph 250 | BQ SI AF |
| 5097G | Capsule 500 mg | 24 | .. | .. | 16.94 | 17.99 | ^a Diclocil ^a Dicloxsig ^a Distaph 500 | BQ SI AF |

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|---|--|-------------|----------------|---------|--|--|---|----------------------------|
| FLUCLOXACILLIN | | | | | | | | |
| CAUTION: | | | | | | | | |
| Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days. | | | | | | | | |
| 5094D | Powder for injection 500 mg | 5 | .. | .. | 15.49 | 16.54 | ^a Flubiclox ^a Flucil | TS AS |
| 5095E | Powder for injection 1 g | 5 | .. | .. | 20.66 | 21.71 | ^a Flubiclox ^a Flucil ^a HH | TS AS |
| | | | | | | | | |
| FLUCLOXACILLIN | | | | | | | | |
| CAUTION: | | | | | | | | |
| Severe cholestatic hepatitis has been reported with this drug. Significant risk factors are age, particularly greater than 55 years, and duration of treatment longer than 14 days. | | | | | | | | |
| Restricted Benefit | | | | | | | | |
| <i>Serious staphylococcal infections.</i> | | | | | | | | |
| 5090X | Capsule 250 mg (as sodium) | 24 | .. | .. | 11.45 | 12.50 | ^a Flopen ^a Staphylex 250 | AS AF |
| 5091Y | Capsule 500 mg (as sodium) | 24 | .. | .. | 16.94 | 17.99 | ^a Flopen ^a Staphylex 500 | AS AF |
| 5257Q | Powder for oral liquid 125 mg (as sodium) per 5 mL, 100 mL | ‡ 1 | .. | .. | # 16.36 | 17.74 | LN | |
| 5258R | Powder for oral liquid 250 mg (as sodium) per 5 mL, 100 mL | ‡ 1 | .. | .. | # 20.07 | 21.45 | LN | |
| | | | | | | | | |
| • Combinations of penicillins, incl. beta-lactamase inhibitors | | | | | | | | |
| AMOXYCILLIN with CLAVULANIC ACID | | | | | | | | |
| CAUTION: | | | | | | | | |
| <i>Hepatotoxicity has been reported with this drug.</i> | | | | | | | | |
| Restricted Benefit | | | | | | | | |
| <i>Infections where resistance to amoxicillin is suspected;</i> | | | | | | | | |
| <i>Infections where resistance to amoxicillin is proven.</i> | | | | | | | | |
| 5008N | Tablet 500 mg-125 mg | 10 | .. | .. | 12.16 | 13.21 | ^a APO-Amoxicillin/ Clavulanic Acid 500/125 ^a Clamoxyl Duo ^a Curam 500/125 ^a GA-Amclav 500/ 125 ^a Moxiclav Duo 500/ 125 | TX AL SZ GM AW |
| | | | | | b1.55 | 13.71 | ^a Augmentin Duo | GK |

continued ☞

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | | |
|-------|---|-------------|----------------|---------|--|--|--|-----------------------------------|----|
| 5006L | Tablet 875 mg-125 mg | 10 | .. | .. | 14.60 | 15.65 | ^a Chem mart Amoxicillin and Clavulanic Acid | CH | |
| | | | | | | | ^a Clamoxyl Duo forte | AL | |
| | | | | | | | ^a Clavycillin 875/125 | CR | |
| | | | | | | | ^a Curam 875/125 | SZ | |
| | | | | | | | ^a GA-Amclav Forte 875/125 | GM | |
| | | | | | | | ^a GenRx Amoxicillin and Clavulanic Acid | GX | |
| | | | | | | | ^a Moxiclav Duo Forte 875/125 | AW | |
| | | | | | | | ^a Terry White Chemists Amoxicillin and Clavulanic Acid | TW | |
| | | | | B2.04 | 16.64 | 15.65 | ^a Augmentin Duo forte | GK | |
| 5009P | Powder for syrup 125 mg-31.25 mg per 5 mL, 75 mL | ‡ 1 | .. | .. | # 12.47 | 13.85 | ^a Clamoxyl | AL | |
| | | | | | | | ^a Curam | SZ | |
| | | | | | B1.51 | # 13.98 | 13.85 | ^a Augmentin | GK |
| 5011R | Powder for syrup 400 mg-57 mg per 5 mL, 60 mL | ‡ 1 | .. | .. | # 13.98 | 15.36 | ^a Clamoxyl Duo 400 | AL | |
| | | | | | | | ^a Curam Duo | SZ | |
| | | | | | B1.54 | # 15.52 | 15.36 | ^a Augmentin Duo 400 | GK |

TICARCILLIN with CLAVULANIC ACID

Restricted Benefit

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent.

| | | | | | | | | |
|-------|--|----|----|----|--------|-------|----------|----|
| 5230G | Powder for injection 3 g-100 mg (solvent required) (code 7043Q applies to above item with approved solvent) | 10 | .. | .. | 163.32 | 32.90 | Timentin | GK |
|-------|--|----|----|----|--------|-------|----------|----|

Other beta-lactam antibacterials

• First-generation cephalosporins

CEFALOTIN

| | | | | | | | | |
|-------|--------------------------|----|----|----|-------|-------|-------------------------------|----|
| 3376Q | Powder for injection 1 g | 10 | .. | .. | 40.09 | 32.90 | ^a Cefalotin Sandoz | SZ |
| | | | | | | | ^a Keflin Neutral | AS |
| | | | | | | | ^a HH | |

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer |
|------------|---|-------------|----------------|---------|--|--|---|
| CEPHALEXIN | | | | | | | |
| 3317N | Capsule 250 mg | 20 | .. | .. | 8.85 | 9.90 | a Cefalexin Sandoz SZ a Cephabell BF a Cephalixin Max XF a Cephatrust 250 MI a Chem mart CH Cephalixin a Cilex GM a GenRx Cephalixin GX a Ialex LN a Ibilex 250 AF a Rancef RA a Sporahehexal HX a Terry White TW Chemists Cephalixin |
| | | | | B3.30 | 12.15 | 9.90 | a Keflex AS |
| 3318P | Capsule 500 mg | 20 | .. | .. | 10.77 | 11.82 | a Cefalexin Sandoz SZ a Cephabell BF a Cephalixin Max XF a Cephatrust 500 MI a Chem mart CH Cephalixin a Cilex GM a GenRx Cephalixin GX a Ialex LN a Ibilex 500 AF a Rancef RA a Sporahehexal HX a Terry White TW Chemists Cephalixin |
| | | | | B4.41 | 15.18 | 11.82 | a Keflex AS |
| 3319Q | Granules for syrup 125 mg per 5 mL, 100 mL | ‡ 1 | .. | .. | # 11.83 | 13.21 | a Cefalexin Sandoz SZ a Chem mart CH Cephalixin a Cilex GM a GenRx Cephalixin GX a Ialex LN a Ibilex 125 AF a Terry White TW Chemists Cephalixin |
| | | | | B3.55 | # 15.38 | 13.21 | a Keflex AS |

continued ↪

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|-------|---|-------------|----------------|---------|--|--|--------------------------------------|----|
| 3320R | Granules for syrup 250 mg per 5 mL, 100 mL | ‡ 1 | .. | .. | # 13.23 | 14.61 | a Cefalexin Sandoz | SZ |
| | | | | | | | a Chem mart | CH |
| | | | | | | | Cephalexin | |
| | | | | | | | a Cilex | GM |
| | | | | | | | a GenRx Cephalexin | GX |
| | | | | | | | a Ialex | LN |
| | | | | | | | a Ibilex 250 | AF |
| | | | | | | | a Terry White | TW |
| | | | | | | | Chemists | |
| | | | | | | | Cephalexin | |
| | | | | B4.38 | # 17.61 | 14.61 | a Keflex | AS |

• **Second-generation cephalosporins**

CEFACTOR

CAUTION:

Serum sickness-like reactions have been reported with this drug, especially in children.

| | | | | | | | | |
|-------|---|-----|----|-------|---------|-------|---------------------------|----|
| 5045M | Tablet 375 mg (sustained release) | 10 | .. | .. | 12.89 | 13.94 | a Cefaclor-GA | GN |
| | | | | | | | a Chem mart | CH |
| | | | | | | | Cefaclor CD | |
| | | | | | | | a Douglas Cefaclor- CD | GM |
| | | | | | | | a GenRx Cefaclor CD | GX |
| | | | | | | | a Karlor CD | LN |
| | | | | | | | a Keflor CD | AF |
| | | | | | | | a Ozcef | RA |
| | | | | | | | a Terry White | TW |
| | | | | | | | Chemists | |
| | | | | | | | Cefaclor CD | |
| | | | | B5.20 | 18.09 | 13.94 | a Ceclor CD | AS |
| 5046N | Powder for oral suspension 125 mg per 5 mL, 100 mL | ‡ 1 | .. | .. | # 13.49 | 14.87 | a Aclor 125 | AW |
| | | | | | | | a Cefaclor Sandoz | SZ |
| | | | | | | | a Chem mart | CH |
| | | | | | | | Cefaclor | |
| | | | | | | | a GenRx Cefaclor | GX |
| | | | | | | | a Keflor | AF |
| | | | | | | | a Ozcef | RA |
| | | | | | | | a Terry White | TW |
| | | | | | | | Chemists | |
| | | | | | | | Cefaclor | |
| | | | | B4.18 | # 17.67 | 14.87 | a Ceclor | AS |
| 5047P | Powder for oral suspension 250 mg per 5 mL, 75 mL | ‡ 1 | .. | .. | # 13.82 | 15.20 | a Aclor 250 | AW |
| | | | | | | | a Cefaclor Sandoz | SZ |
| | | | | | | | a Chem mart | CH |
| | | | | | | | Cefaclor | |
| | | | | | | | a GenRx Cefaclor | GX |
| | | | | | | | a Keflor | AF |
| | | | | | | | a Ozcef | RA |
| | | | | | | | a Terry White | TW |
| | | | | | | | Chemists | |
| | | | | | | | Cefaclor | |
| | | | | B4.37 | # 18.19 | 15.20 | a Ceclor | AS |

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|------|---|-------------|----------------|---------|--|--|--------------------------------------|--|
|------|---|-------------|----------------|---------|--|--|--------------------------------------|--|

CEFUROXIME AXETIL

| | | | | | | | | |
|-------|----------------------|----|----|----|-------|-------|--------|----|
| 5052X | Tablet 250 mg (base) | 14 | .. | .. | 18.62 | 19.67 | Zinnat | GK |
|-------|----------------------|----|----|----|-------|-------|--------|----|

• Third-generation cephalosporins

CEFOTAXIME

Restricted Benefit

Infections where positive bacteriological evidence confirms that this antibiotic is an appropriate therapeutic agent.

| | | | | | | | | |
|-------|--------------------------|----|----|----|-----------------|---------------------------|---|----|
| 5048Q | Powder for injection 1 g | 10 | .. | .. | 27.27 B24.80 | 28.32 * 52.02 28.27 | ^a HH ^a Cefotaxime Sandoz | SZ |
| 5049R | Powder for injection 2 g | 10 | .. | .. | 44.35 B45.60 | 32.90 * 89.92 32.90 | ^a HH ^a Cefotaxime Sandoz | SZ |

Sulfonamides and trimethoprim

• Combinations of sulfonamides and trimethoprim, incl. derivatives

TRIMETHOPRIM with SULFAMETHOXAZOLE

CAUTION:

There is an increased risk of severe adverse reactions with this combination in the elderly.

| | | | | | | | | |
|-------|--|-----|----|-------|---------------|----------------|---|----------|
| 3389J | Tablet 80 mg-400 mg | 10 | .. | .. | 8.67 | 9.72 | Resprim | AF |
| 3390K | Tablet 160 mg-800 mg | 10 | .. | .. | 9.39 | 10.44 | ^a Bactrim DS ^a Resprim Forte | RO AF |
| | | | | B1.10 | 10.49 | 10.44 | ^a Septrin Forte | SI |
| 3391L | Oral suspension 40 mg-200 mg per 5 mL, 100 mL | ‡ 1 | .. | .. | 9.05 B1.46 | 10.10 10.10 | Bactrim Septrin | RO SI |

Macrolides, lincosamides and streptogramins

• Macrolides

ERYTHROMYCIN

| | | | | | | | | |
|-------|----------------|----|----|----|---------------|----------------|--|----------|
| 3325B | Capsule 250 mg | 25 | .. | .. | 9.43 B1.35 | 10.48 10.48 | ^a DBL Erythromycin ^a Eryc | FA HH |
|-------|----------------|----|----|----|---------------|----------------|--|----------|

ERYTHROMYCIN ETHYL SUCCINATE

| | | | | | | | | |
|-------|--|-----|----|----|-----------------------------|-------------------------|--|----------|
| 3336N | Tablet 400 mg (base) | 25 | .. | .. | 10.92 B2.80 | 11.97 13.72 11.97 | ^a E-Mycin ^a E.E.S. 400 Filmtab | AF LM |
| 3334L | Powder for oral liquid 200 mg (base) per 5 mL, 100 mL | ‡ 1 | .. | .. | # 12.31 B2.86 # 15.17 | 13.69 13.69 | ^a E-Mycin 200 ^a E.E.S. 200 | AF LM |
| 3337P | Powder for oral liquid 400 mg (base) per 5 mL, 100 mL | ‡ 1 | .. | .. | # 13.39 B2.89 # 16.28 | 14.77 14.77 | ^a E-Mycin 400 ^a E.E.S. Granules | AF LM |

ERYTHROMYCIN LACTOBIONATE

| | | | | | | | | |
|-------|-------------------------------------|---|----|----|---------|-------|-----------------|----|
| 5088T | Powder for I.V. infusion 1 g (base) | 5 | .. | .. | * 51.37 | 32.90 | Erythrocin-I.V. | LM |
|-------|-------------------------------------|---|----|----|---------|-------|-----------------|----|

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|--|---|-------------|----------------|---------|--|--|--|----------------|
| • Lincosamides | | | | | | | | |
| CLINDAMYCIN | | | | | | | | |
| <u>Restricted Benefit</u> | | | | | | | | |
| <i>Gram-positive coccal infections where these cannot be safely and effectively treated with a penicillin.</i> | | | | | | | | |
| 5057E | Capsule 150 mg | 24 | .. | .. | 20.30 B1.43 | 21.35 21.35 | ^a Cleocin ^a Dalacin C | KR PH |
| LINCOMYCIN | | | | | | | | |
| 5144R | Injection 600 mg in 2 mL | 5 | .. | .. | 33.74 | 32.90 | Lincocin | PH |
| Other antibacterials | | | | | | | | |
| • Glycopeptide antibacterials | | | | | | | | |
| VANCOMYCIN | | | | | | | | |
| <u>Restricted Benefit</u> | | | | | | | | |
| <i>Prophylaxis of endocarditis in patients hypersensitive to penicillin.</i> | | | | | | | | |
| 3323X | Powder for injection 500 mg (500,000 i.u.) vancomycin activity | 2 | .. | .. | * 45.80 | 32.90 | ^a Vancocin CP ^a Vancomycin Sandoz ^a HH | AS SZ |
| 5083M | Powder for injection 1 g (1,000,000 i.u.) vancomycin activity | 1 | .. | .. | 45.79 | 32.90 | ^a Vancomycin Sandoz ^a HH | SZ |
| • Imidazole derivatives | | | | | | | | |
| METRONIDAZOLE | | | | | | | | |
| 3339R | Tablet 200 mg | 21 | .. | .. | 7.96 B2.30 | 9.01 9.01 | ^a Metrogyl 200 ^a Metronide 200 ^a Flagyl | AF AV SW |
| 5159M | Tablet 400 mg | 5 | .. | .. | 7.88 | 8.93 | Metrogyl 400 | AF |
| 5157K | Suppositories 500 mg, 10 | ‡ 1 | .. | .. | 23.16 | 24.21 | Flagyl | SW |
| <hr/> | | | | | | | | |
| METRONIDAZOLE | | | | | | | | |
| <u>Restricted Benefit</u> | | | | | | | | |
| <i>Treatment of anaerobic infections.</i> | | | | | | | | |
| 5155H | Tablet 400 mg | 21 | .. | .. | 10.03 B2.30 | 11.08 11.08 | ^a Metrogyl 400 ^a Metronide 400 ^a Flagyl | AF AV SW |
| <hr/> | | | | | | | | |

continued ☞

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|---|--|-------------|----------------|---------|--|--|---|----|
| Restricted Benefit | | | | | | | | |
| <i>Treatment, in a hospital, of acute anaerobic sepsis.</i> | | | | | | | | |
| 5154G | <i>I.V. infusion 500 mg in 100 mL</i> | 5 | .. | .. | * 31.97 | 32.90 | ^a BX | |
| | | | | .. | * 32.00 | 32.90 | ^a DBL | HH |
| | | | | | | | <i>Metronidazole Intravenous Infusion</i> | |
| | | | | | | | ^a <i>Metronidazole Sandoz</i> | SZ |
| METRONIDAZOLE BENZOATE | | | | | | | | |
| 3341W | Oral suspension 320 mg per 5 mL (equivalent to 200 mg metronidazole in 5 mL), 100 mL | ‡ 1 | .. | .. | 17.17 | 18.22 | Flagyl S | SW |

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer |
|------|---|-------------|----------------|---------|--|--|--------------------------------------|
|------|---|-------------|----------------|---------|--|--|--------------------------------------|

MUSCULO-SKELETAL SYSTEM

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

Antiinflammatory and antirheumatic products, non-steroids

• *Acetic acid derivatives and related substances*

DICLOFENAC SODIUM

| | | | | | | | | |
|-------|--------------------|----|----|----|---------|-------|--------------|----|
| 5079H | Suppository 100 mg | 40 | .. | .. | * 24.92 | 25.97 | Voltaren 100 | NV |
|-------|--------------------|----|----|----|---------|-------|--------------|----|

DICLOFENAC SODIUM

Restricted Benefit

Chronic arthropathies (including osteoarthritis) with an inflammatory component;

Bone pain due to malignant disease.

| | | | | | | | | |
|-------|-------------------------------|-----|----|----|---------|-------|------------------------|----|
| 5076E | Tablet 25 mg (enteric coated) | 100 | .. | .. | * 13.06 | 14.11 | ^a Chem mart | CH |
|-------|-------------------------------|-----|----|----|---------|-------|------------------------|----|

Diclofenac

^a Clonac 25 AW

^a Diclofenac-GA GN

^a Diclohexal SZ

^a Dinac GM

^a GenRx Diclofenac GX

^a Terry White TW

Chemists

Diclofenac

.. 13.07 14.12 ^a Fenac 25 AF

bl.96 * 15.02 14.11 ^a Voltaren 25 NV

| | | | | | | | | |
|-------|-------------------------------|----|----|----|-------|-------|------------------------|----|
| 5077F | Tablet 50 mg (enteric coated) | 50 | .. | .. | 11.05 | 12.10 | ^a Chem mart | CH |
|-------|-------------------------------|----|----|----|-------|-------|------------------------|----|

Diclofenac

^a Clonac 50 AW

^a Diclohexal SZ

^a Dinac GM

^a Fenac AF

^a GenRx Diclofenac GX

^a Terry White TW

Chemists

Diclofenac

bl.96 13.01 12.10 ^a Voltaren 50 NV

INDOMETHACIN

| | | | | | | | | |
|-------|--------------------|----|----|----|---------|-------|---------|----|
| 5128X | Suppository 100 mg | 40 | .. | .. | * 22.50 | 23.55 | Indocid | AS |
|-------|--------------------|----|----|----|---------|-------|---------|----|

continued ↗

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|---|---|-------------|----------------|---------|--|--|---|----------------------|
| INDOMETHACIN | | | | | | | | |
| Restricted Benefit | | | | | | | | |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i> | | | | | | | | |
| <i>Bone pain due to malignant disease.</i> | | | | | | | | |
| 5126T | Capsule 25 mg | 100 | .. | .. | * 12.08 b2.16 | 13.13 13.13 | ^a Arthrexin ^a Indocid | AF AS |
| SULINDAC | | | | | | | | |
| Restricted Benefit | | | | | | | | |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i> | | | | | | | | |
| <i>Bone pain due to malignant disease.</i> | | | | | | | | |
| 5217N | Tablet 100 mg | 100 | .. | .. | * 16.34 | 17.39 | Actin | AF |
| 5218P | Tablet 200 mg | 50 | .. | .. | 15.28 | 16.33 | Actin 200 | AF |
| • Oxicams | | | | | | | | |
| PIROXICAM | | | | | | | | |
| Restricted Benefit | | | | | | | | |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component.</i> | | | | | | | | |
| 5201R | Dispersible tablet 10 mg | 50 | .. | .. | 12.50 | 13.55 | Mobilis D-10 | AF |
| 5202T | Dispersible tablet 20 mg | 25 | .. | .. | 12.20 b2.64 | 13.25 14.84 | ^a Mobilis D-20 ^a Feldene-D | AF PF |
| 5203W | Capsule 10 mg | 50 | .. | .. | 12.50 | 13.55 | ^a Chem mart Piroxicam ^a GenRx Piroxicam ^a Mobilis 10 ^a Terry White Chemists Piroxicam | CH GX AF TW |
| | | | | | b2.66 | 15.16 | ^a Feldene | PF |
| 5204X | Capsule 20 mg | 25 | .. | .. | 12.20 | 13.25 | ^a Chem mart Piroxicam ^a GenRx Piroxicam ^a Mobilis 20 ^a Terry White Chemists Piroxicam | CH GX AF TW |
| | | | | | b2.64 | 14.84 | ^a Feldene | PF |
| • Propionic acid derivatives | | | | | | | | |
| IBUPROFEN | | | | | | | | |
| 5124Q | Tablet 400 mg | 30 | .. | .. | 9.19 | 10.24 | Brufen | AB |

continued ↻

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|---|---|-------------|----------------|---------|--|--|---|----------|
| IBUPROFEN | | | | | | | | |
| Restricted Benefit | | | | | | | | |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i> | | | | | | | | |
| <i>Bone pain due to malignant disease.</i> | | | | | | | | |
| 5121M | Tablet 200 mg | 100 | .. | .. | * 12.06 | 13.11 | Rafen 200 | AF |
| 5123P | Tablet 400 mg | 90 | .. | .. | * 14.73 | 15.78 | Brufen | AB |
| KETOPROFEN | | | | | | | | |
| 5139L | Suppository 100 mg | 40 | .. | .. | * 25.30 | 26.35 | Orudis | SW |
| KETOPROFEN | | | | | | | | |
| Restricted Benefit | | | | | | | | |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component.</i> | | | | | | | | |
| 5136H | Capsule 200 mg (sustained release) | 28 | .. | .. | 19.63 B2.26 | 20.68 20.68 | ^a Oruvail SR ^a Orudis SR 200 | AV SW |
| NAPROXEN | | | | | | | | |
| Restricted Benefit | | | | | | | | |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i> | | | | | | | | |
| <i>Bone pain due to malignant disease.</i> | | | | | | | | |
| 5176K | Tablet 250 mg | 100 | .. | .. | * 13.72 B2.34 | 14.77 14.77 | ^a Inza 250 ^a Naprosyn | AF RO |
| 5177L | Tablet 500 mg | 50 | .. | .. | 12.91 B1.36 | 13.96 14.27 | ^a Inza 500 ^a Naprosyn | AF RO |
| 5178M | Tablet 750 mg (sustained release) | 28 | .. | .. | 12.38 B1.27 | 13.43 13.65 | ^a Proxen SR 750 ^a Naprosyn SR750 | MD RO |
| 5179N | Tablet 1 g (sustained release) | 28 | .. | .. | 14.37 B1.34 | 15.42 15.42 | ^a Proxen SR 1000 ^a Naprosyn SR1000 | MD RO |
| NAPROXEN SODIUM | | | | | | | | |
| Restricted Benefit | | | | | | | | |
| <i>Chronic arthropathies (including osteoarthritis) with an inflammatory component;</i> | | | | | | | | |
| <i>Bone pain due to malignant disease.</i> | | | | | | | | |
| 5186Y | Tablet 550 mg | 50 | .. | .. | 13.10 B2.29 | 14.15 14.15 | ^a Crysanal ^a Anaprox 550 | MD RO |
| NOTE: | | | | | | | | |
| Naproxen sodium 550 mg is approximately equivalent to 500 mg of naproxen acid. | | | | | | | | |

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer |
|------|---|-------------|----------------|---------|--|--|--------------------------------------|
|------|---|-------------|----------------|---------|--|--|--------------------------------------|

NERVOUS SYSTEM

ANALGESICS

Opioids

• *Natural opium alkaloids*

CODEINE PHOSPHATE

| | | | | | | | |
|-------|--------------|----|----|----|-------|-------|----|
| 5063L | Tablet 30 mg | 20 | .. | .. | 16.87 | 17.92 | FM |
|-------|--------------|----|----|----|-------|-------|----|

NOTE:

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

CODEINE PHOSPHATE with PARACETAMOL

| | | | | | | | | |
|-------|---------------------|----|----|-------|-------|------|--|----|
| 3316M | Tablet 30 mg-500 mg | 20 | .. | .. | 8.08 | 9.13 | ^a APO- Paracetamol/ Codeine 500/30 | TX |
| | | | | | | | ^a Codalgin Forte | FM |
| | | | | | | | ^a Codapane Forte | AL |
| | | | | | | | ^a Comfarol Forte | SZ |
| | | | | | | | ^a Dolaforte | CO |
| | | | | | | | ^a Prodeine Forte | AV |
| | | | | b2.80 | 10.88 | 9.13 | ^a Panadeine Forte | SW |

HYDROMORPHONE HYDROCHLORIDE

CAUTION:

The risk of drug dependence is high.

| | | | | | | | | |
|-------|-------------------------|---|----|----|-------|-------|-------------|----|
| 5129Y | Injection 2 mg in 1 mL | 5 | .. | .. | 13.94 | 14.99 | Dilaudid | MF |
| 5130B | Injection 10 mg in 1 mL | 5 | .. | .. | 19.30 | 20.35 | Dilaudid-HP | MF |
| 5131C | Injection 50 mg in 5 mL | 5 | .. | .. | 47.50 | 32.90 | Dilaudid-HP | MF |

NOTE:

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

HYDROMORPHONE HYDROCHLORIDE

CAUTION:

The risk of drug dependence is high.

Restricted Benefit

Severe disabling pain not responding to non-narcotic analgesics.

| | | | | | | | | |
|-------|---------------------------------|----|----|----|-------|-------|----------|----|
| 5115F | Tablet 2 mg | 20 | .. | .. | 14.22 | 15.27 | Dilaudid | MF |
| 5116G | Tablet 4 mg | 20 | .. | .. | 19.28 | 20.33 | Dilaudid | MF |
| 5117H | Tablet 8 mg | 20 | .. | .. | 29.04 | 30.09 | Dilaudid | MF |
| 5132D | Oral liquid 1 mg per mL, 473 mL | 1 | .. | .. | 49.52 | 32.90 | Dilaudid | MF |

NOTE:

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

continued ↗

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|---|---|-------------|----------------|---------|--|--|--------------------------------------|----|
| Restricted Benefit | | | | | | | | |
| <i>Chronic severe disabling pain not responding to non-narcotic analgesics.</i> | | | | | | | | |
| 3357Q | Tablet 8 mg (modified release) | 10 | .. | .. | 28.61 | 29.66 | Jurnista | JC |
| 3358R | Tablet 16 mg (modified release) | 10 | .. | .. | 41.32 | 32.90 | Jurnista | JC |
| 3367F | Tablet 32 mg (modified release) | 10 | .. | .. | 65.97 | 32.90 | Jurnista | JC |
| 3368G | Tablet 64 mg (modified release) | 10 | .. | .. | 109.31 | 32.90 | Jurnista | JC |
| NOTE: | | | | | | | | |
| <i>Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.</i> | | | | | | | | |
| MORPHINE HYDROCHLORIDE | | | | | | | | |
| CAUTION: | | | | | | | | |
| <i>The risk of drug dependence is high.</i> | | | | | | | | |
| Restricted Benefit | | | | | | | | |
| <i>Severe disabling pain not responding to non-narcotic analgesics.</i> | | | | | | | | |
| 5237P | Oral solution 2 mg per mL, 200 mL | 1 | .. | .. | 17.90 | 18.95 | Ordine 2 | MF |
| 5238Q | Oral solution 5 mg per mL, 200 mL | 1 | .. | .. | 20.45 | 21.50 | Ordine 5 | MF |
| 5239R | Oral solution 10 mg per mL, 200 mL | 1 | .. | .. | 24.47 | 25.52 | Ordine 10 | MF |
| NOTE: | | | | | | | | |
| <i>Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.</i> | | | | | | | | |
| MORPHINE SULFATE | | | | | | | | |
| CAUTION: | | | | | | | | |
| <i>The risk of drug dependence is high.</i> | | | | | | | | |
| 5168B | Injection 10 mg in 1 mL | 5 | .. | .. | 14.20 | 15.25 | HH | |
| 5169C | Injection 15 mg in 1 mL | 5 | .. | .. | 14.56 | 15.61 | HH | |
| 5170D | Injection 30 mg in 1 mL | 5 | .. | .. | 16.04 | 17.09 | HH | |
| NOTE: | | | | | | | | |
| <i>Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.</i> | | | | | | | | |
| MORPHINE SULFATE | | | | | | | | |
| CAUTION: | | | | | | | | |
| <i>The risk of drug dependence is high.</i> | | | | | | | | |
| Restricted Benefit | | | | | | | | |
| <i>Severe disabling pain not responding to non-narcotic analgesics.</i> | | | | | | | | |
| 5163R | Tablet 30 mg | 20 | .. | .. | 14.24 | 15.29 | Anamorph | FM |
| NOTE: | | | | | | | | |
| <i>Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.</i> | | | | | | | | |

continued ↻

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|---|--|-------------|----------------|---------|--|--|---|----------|
| Restricted Benefit | | | | | | | | |
| <i>Chronic severe disabling pain not responding to non-narcotic analgesics.</i> | | | | | | | | |
| 5162Q | Tablet 5 mg (controlled release) | 20 | .. | .. | 15.42 | 16.47 | MS Contin | MF |
| 5164T | Tablet 10 mg (controlled release) | 20 | .. | .. | 17.24 | 18.29 | ^a Momex SR 10 ^a MS Contin | SI MF |
| 5161P | Tablet 15 mg (controlled release) | 20 | .. | .. | 20.35 | 21.40 | MS Contin | MF |
| 5165W | Tablet 30 mg (controlled release) | 20 | .. | .. | 29.03 | 30.08 | ^a Momex SR 30 ^a MS Contin | SI MF |
| 5166X | Tablet 60 mg (controlled release) | 20 | .. | .. | 44.01 | 32.90 | ^a Momex SR 60 ^a MS Contin | SI MF |
| 5167Y | Tablet 100 mg (controlled release) | 20 | .. | .. | 56.49 | 32.90 | ^a Momex SR 100 ^a MS Contin | SI MF |
| 5246D | Capsule 10 mg (containing sustained release pellets) | 20 | .. | .. | 17.24 | 18.29 | Kapanol | GK |
| 5240T | Capsule 20 mg (containing sustained release pellets) | 20 | .. | .. | 20.94 | 21.99 | Kapanol | GK |
| 5064M | Capsule 30 mg (controlled release) | 10 | .. | .. | 20.35 | 21.40 | MS Mono | MF |
| 5241W | Capsule 50 mg (containing sustained release pellets) | 20 | .. | .. | 34.55 | 32.90 | Kapanol | GK |
| 5065N | Capsule 60 mg (controlled release) | 10 | .. | .. | 29.03 | 30.08 | MS Mono | MF |
| 5066P | Capsule 90 mg (controlled release) | 10 | .. | .. | 33.15 | 32.90 | MS Mono | MF |
| 5242X | Capsule 100 mg (containing sustained release pellets) | 20 | .. | .. | 55.10 | 32.90 | Kapanol | GK |
| 5067Q | Capsule 120 mg (controlled release) | 10 | .. | .. | 44.01 | 32.90 | MS Mono | MF |
| 5171E | Sachet containing controlled release granules for oral suspension, 20 mg per sachet | 20 | .. | .. | 44.40 | 32.90 | MS Contin Suspension 20 mg | MF |
| 5243Y | Sachet containing controlled release granules for oral suspension, 30 mg per sachet | 20 | .. | .. | 45.48 | 32.90 | MS Contin Suspension 30 mg | MF |
| 5244B | Sachet containing controlled release granules for oral suspension, 60 mg per sachet | 20 | .. | .. | 50.16 | 32.90 | MS Contin Suspension 60 mg | MF |
| 5245C | Sachet containing controlled release granules for oral suspension, 100 mg per sachet | 20 | .. | .. | 60.23 | 32.90 | MS Contin Suspension 100 mg | MF |

NOTE:

Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer |
|------|---|-------------|----------------|---------|--|--|--------------------------------------|
|------|---|-------------|----------------|---------|--|--|--------------------------------------|

OXYCODONE**CAUTION:***The risk of drug dependence is high.***Restricted Benefit***Severe disabling pain not responding to non-narcotic analgesics.*

| | | | | | | | | |
|-------|-------------------|----|----|----|-------|-------|-----------|----|
| 5194J | Suppository 30 mg | 12 | .. | .. | 43.66 | 32.90 | Proladone | PL |
|-------|-------------------|----|----|----|-------|-------|-----------|----|

NOTE:*Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.***OXYCODONE HYDROCHLORIDE****CAUTION:***The risk of drug dependence is high.***Restricted Benefit***Severe disabling pain not responding to non-narcotic analgesics.*

| | | | | | | | | |
|-------|-------------------------------------|----|----|----|-------|-------|---------------------------|----|
| 5195K | Tablet 5 mg | 20 | .. | .. | 12.30 | 13.35 | Endone | SI |
| 5191F | Capsule 5 mg | 20 | .. | .. | 12.30 | 13.35 | OxyNorm | MF |
| 5197M | Capsule 10 mg | 20 | .. | .. | 15.42 | 16.47 | OxyNorm | MF |
| 5198N | Capsule 20 mg | 20 | .. | .. | 20.15 | 21.20 | OxyNorm | MF |
| 5190E | Oral solution 5 mg per 5 mL, 250 mL | 1 | .. | .. | 20.72 | 21.77 | OxyNorm Liquid 5mg/5mL | MF |

NOTE:*Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.***Restricted Benefit***Chronic severe disabling pain not responding to non-narcotic analgesics.*

| | | | | | | | | |
|-------|-----------------------------------|----|----|----|-------|-------|-----------|----|
| 5227D | Tablet 5 mg (controlled release) | 20 | .. | .. | 21.18 | 22.23 | OxyContin | MF |
| 5247E | Tablet 10 mg (controlled release) | 20 | .. | .. | 21.95 | 23.00 | OxyContin | MF |
| 5015Y | Tablet 15 mg (controlled release) | 20 | .. | .. | 27.93 | 28.98 | OxyContin | MF |
| 5248F | Tablet 20 mg (controlled release) | 20 | .. | .. | 31.87 | 32.90 | OxyContin | MF |
| 5016B | Tablet 30 mg (controlled release) | 20 | .. | .. | 41.22 | 32.90 | OxyContin | MF |
| 5249G | Tablet 40 mg (controlled release) | 20 | .. | .. | 48.35 | 32.90 | OxyContin | MF |
| 5250H | Tablet 80 mg (controlled release) | 20 | .. | .. | 71.70 | 32.90 | OxyContin | MF |

NOTE:*Prescribing of drugs of addiction by dentists is not permitted in some States/Territories.*

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|--|---|-------------|----------------|---------|--|--|--|--|
| • Other opioids | | | | | | | | |
| TRAMADOL HYDROCHLORIDE | | | | | | | | |
| <u>Restricted Benefit</u> | | | | | | | | |
| <i>For acute pain where aspirin and/or paracetamol alone are inappropriate or have failed;</i> | | | | | | | | |
| <i>For dosage titration in chronic pain where aspirin and/or paracetamol alone are inappropriate or have failed.</i> | | | | | | | | |
| 5232J | Capsule 50 mg | 20 | .. | .. | 9.16 | 10.21 | ^a Chem mart Tramadol | CH |
| | | | | | | | ^a GenRx Tramadol | GX |
| | | | | | | | ^a Terry White Chemists Tramadol | TW |
| | | | | | | | ^a Tramedo | AF |
| | | | | | | | ^a Zydol | AW |
| | | | | B2.42 | 11.58 | 10.21 | ^a Tramal | CS |
| <u>Restricted Benefit</u> | | | | | | | | |
| <i>For pain where aspirin and/or paracetamol alone are inappropriate or have failed.</i> | | | | | | | | |
| 3338Q | Tablet 50 mg (twice daily sustained release) | 20 | .. | .. | 11.63 | 12.68 | Tramal SR 50 | CS |
| 5234L | Tablet 100 mg (twice daily sustained release) | 20 | .. | .. | 13.86 | 14.91 | ^a APO-Tramadol SR ^a Chem mart Tramadol SR ^a Terry White Chemists Tramadol SR ^a Tramahexal SR ^a Tramedo SR 100 ^a Zydol SR 100 ^a Tramal SR 100 | TX CH TW SZ AF AW CS |
| | | | | B4.51 | 18.37 | 14.91 | | |
| 5001F | Tablet 100 mg (once a day extended release) | 10 | .. | .. | 13.37 | 14.42 | Durotram XR | IA |
| 5235M | Tablet 150 mg (twice daily sustained release) | 20 | .. | .. | 16.45 | 17.50 | ^a APO-Tramadol SR ^a Chem mart Tramadol SR ^a Terry White Chemists Tramadol SR ^a Tramahexal SR ^a Tramedo SR 150 ^a Zydol SR 150 ^a Tramal SR 150 | TX CH TW SZ AF AW CS |
| | | | | B5.37 | 21.82 | 17.50 | | |

continued ↗

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|--|---|-------------|----------------|---------|--|--|--|--|
| 5236N | Tablet 200 mg (twice daily sustained release) | 20 | .. | .. | 18.63 | 19.68 | ^a APO-Tramadol SR ^a Chem mart ^a Terry White Chemists Tramadol SR ^a TramaHexal SR ^a Tramedo SR 200 ^a Zydol SR 200 ^a Tramal SR 200 | TX CH TW SZ AF AW CS |
| 5002G | Tablet 200 mg (once a day extended release) | 10 | .. | .. | 16.34 | 17.39 | Durotram XR | IA |
| 5003H | Tablet 300 mg (once a day extended release) | 10 | .. | .. | 19.79 | 20.84 | Durotram XR | IA |
| 5150C | Oral drops 100 mg per mL, 10 mL | ‡ 1 | .. | .. | 13.71 | 14.76 | Tramal | CS |
| Restricted Benefit | | | | | | | | |
| <i>Short-term treatment of acute pain.</i> | | | | | | | | |
| 5231H | Injection 100 mg in 2 mL | 5 | .. | .. | 14.30 | 15.35 | Tramal 100 | CS |
| Other analgesics and antipyretics | | | | | | | | |
| • Salicylic acid and derivatives | | | | | | | | |
| ASPIRIN | | | | | | | | |
| 5018D | Tablet 300 mg (dispersible) | 96 | .. | .. | 8.59 | 9.64 | Solprin | RC |
| • Anilides | | | | | | | | |
| PARACETAMOL | | | | | | | | |
| 5196L | Tablet 500 mg | 100 | .. | .. | 8.42 | 9.47 | ^a APO-Paracetamol ^a Chem mart Chemadol ^a Dymadon P ^a Febridol ^a Panamax ^a Paracetamol Sandoz ^a Paralgin ^a Pharmacy Choice Paracetamol ^a Terry White Chemists Paracetamol | TX CH PC GM SW SZ FM YM TW |
| 3348F | Oral liquid 120 mg per 5 mL, 100 mL | ‡ 1 | .. | .. | 9.38 | 10.43 | Panamax | SW |
| 3349G | Oral liquid 240 mg per 5 mL, 200 mL | ‡ 1 | .. | .. | 10.68 | 11.73 | Panamax 240 Elixir | SW |

continued ↪

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer |
|-------------------------------|---|-------------|----------------|---------|--|--|---|
| PARACETAMOL | | | | | | | |
| Restricted Benefit | | | | | | | |
| Chronic arthropathies. | | | | | | | |
| 5224Y | Tablet 500 mg | 300 | .. | .. | * 12.42 | 13.47 | ^a APO-Paracetamol TX ^a Chem mart CH Chemadol ^a Dymadon P PC ^a Febridol GM ^a Panamax SW ^a Paracetamol SZ Sandoz ^a Paralgin FM ^a Pharmacy Choice YM Paracetamol ^a Terry White TW Chemists Paracetamol |

| |
|-----------------------|
| ANTIEPILEPTICS |
|-----------------------|

Antiepileptics• **Carboxamide derivatives**

CARBAMAZEPINE

| | | | | | | | |
|-------|--|-----|----|-------|-------|-------|---|
| 5039F | Tablet 100 mg | 200 | .. | .. | 19.14 | 20.19 | ^a Carbamazepine SZ Sandoz |
| | | | | B2.55 | 21.69 | 20.19 | ^a Tegretol 100 NV |
| 5040G | Tablet 200 mg | 200 | .. | .. | 30.20 | 31.25 | ^a Carbamazepine SZ Sandoz |
| | | | | B2.74 | 32.94 | 31.25 | ^a Teril AF ^a Tegretol 200 NV |
| 5038E | Tablet 200 mg (controlled release) | 200 | .. | .. | 30.69 | 31.74 | Tegretol CR 200 NV |
| 5037D | Tablet 400 mg (controlled release) | 200 | .. | .. | 51.02 | 32.90 | Tegretol CR 400 NV |
| 5041H | Oral suspension 100 mg per 5 mL, 300 mL | ‡ 1 | .. | .. | 21.35 | 22.40 | Tegretol Liquid NV |

| |
|-----------------------------|
| ANTI-PARKINSON DRUGS |
|-----------------------------|

Anticholinergic agents• **Ethers of tropine or tropine derivatives**

BENZTROPINE MESYLATE

| | | | | | | | |
|-------|------------------------|---|----|----|-------|-------|-------------|
| 5031T | Injection 2 mg in 2 mL | 5 | .. | .. | 22.84 | 23.89 | Cogentin FK |
|-------|------------------------|---|----|----|-------|-------|-------------|

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer | |
|-------------------------------------|---|-------------|----------------|---------|--|--|--|----------------------|
| PSYCHOLEPTICS | | | | | | | | |
| Anxiolytics | | | | | | | | |
| • Benzodiazepine derivatives | | | | | | | | |
| DIAZEPAM | | | | | | | | |
| 5071X | Tablet 2 mg | 50 | .. | .. | 7.79 | 8.84 | ^a Antenex 2 ^a Valpam 2 | AF SI |
| | | | | b0.59 | 8.38 | 8.84 | Ducene | SU |
| | | | | b0.86 | 8.65 | 8.84 | ^a Valium | RO |
| 5072Y | Tablet 5 mg | 50 | .. | .. | 7.93 | 8.98 | ^a Antenex 5 ^a Diazepam-DP ^a Ranzepam ^a Valpam 5 | AF GM RA SI |
| | | | | b0.63 | 8.56 | 8.98 | Ducene | SU |
| | | | | b0.88 | 8.81 | 8.98 | ^a Valium | RO |
| 5073B | Injection 10 mg in 2 mL | 5 | .. | .. | 12.29 | 13.34 | HH | |
| OXAZEPAM | | | | | | | | |
| 5192G | Tablet 15 mg | 25 | .. | .. | 7.67 | 8.72 | ^a Alepam 15 ^a Serepax | AF SI |
| | | | | b1.75 | 9.42 | 8.72 | | |
| 5193H | Tablet 30 mg | 25 | .. | .. | 7.86 | 8.91 | ^a Alepam 30 ^a Murelax ^a Serepax | AF FM SI |
| | | | | b1.86 | 9.72 | 8.91 | | |
| Hypnotics and sedatives | | | | | | | | |
| • Benzodiazepine derivatives | | | | | | | | |
| NITRAZEPAM | | | | | | | | |
| 5189D | Tablet 5 mg | 25 | .. | .. | 7.89 | 8.94 | ^a Alodorm ^a Mogadon | AF VT |
| | | | | b1.53 | 9.42 | 8.94 | | |
| TEMAZEPAM | | | | | | | | |
| 5221T | Tablet 10 mg | 25 | .. | .. | 7.71 | 8.76 | ^a APO-Temazepam ^a Temaze ^a Temtabs ^a Normison | TX AF FM SI |
| | | | | b1.21 | 8.92 | 8.76 | | |

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer |
|------|---|-------------|----------------|---------|--|--|--------------------------------------|
|------|---|-------------|----------------|---------|--|--|--------------------------------------|

RESPIRATORY SYSTEM

DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES

Adrenergics for systemic use

- *Alpha- and beta-adrenoceptor agonists*

ADRENALINE

| | | | | | | | |
|-------|-------------------------------------|---|----|----|-------|-------|----|
| 5004J | Injection 1 mg in 1 mL (1 in 1,000) | 5 | .. | .. | 20.34 | 21.39 | AP |
|-------|-------------------------------------|---|----|----|-------|-------|----|

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer |
|------|---|-------------|----------------|---------|--|--|--------------------------------------|
|------|---|-------------|----------------|---------|--|--|--------------------------------------|

SENSORY ORGANS

OPHTHALMOLOGICALS

Antiinfectives

- *Antibiotics*

CHLORAMPHENICOL

| | | | | | | | | |
|-------|-------------------------------------|-----|----|----|-------|-------|---------------------------|----------|
| 5055C | Eye drops 5 mg per mL (0.5%), 10 mL | ‡ 1 | .. | .. | 11.00 | 12.05 | Chloromycetin Chlorsig | PF SI |
|-------|-------------------------------------|-----|----|----|-------|-------|---------------------------|----------|

| Code | Name, Restriction, Manner of Administration and Form | Max. Qty | No. of Rpts | Premium | Dispensed Price for Max. Qty \$ | Maximum Recordable Value for Safety Net \$ | Proprietary Name and Manufacturer |
|------|---|-------------|----------------|---------|--|--|--------------------------------------|
|------|---|-------------|----------------|---------|--|--|--------------------------------------|

VARIOUS

ALL OTHER THERAPEUTIC PRODUCTS

All other therapeutic products

- **Antidotes**

NALOXONE HYDROCHLORIDE

| | | | | | | | |
|-------|----------------------------------|---|----|----|-------|-------|-----------------------|
| 5174H | Injection 800 micrograms in 2 mL | 1 | .. | .. | 29.86 | 30.91 | Naloxone Min-I-Jet CS |
| 5175J | Injection 2 mg in 5 mL | 1 | .. | .. | 43.49 | 32.90 | Naloxone Min-I-Jet CS |

ALL OTHER NON-THERAPEUTIC PRODUCTS

All other non-therapeutic products

- **Solvents and diluting agents, incl. irrigating solutions**

SODIUM CHLORIDE

| | | | | | | | |
|-------|-------------------------------------|---|----|----|-------|-------|----|
| 5211G | Injection 9 mg per mL (0.9%), 10 mL | 5 | .. | .. | 16.69 | 17.74 | PF |
|-------|-------------------------------------|---|----|----|-------|-------|----|

GENERIC/PROPRIETARY INDEX

GENERIC/PROPRIETARY INDEX

| | | | |
|----------|--|---|----|
| A | | <i>BenPen</i> (CS) | 33 |
| | <i>Abbccillin-V</i> (SI) | BENZATHINE BENZYLPENICILLIN | 33 |
| | <i>Abbccillin-VK Filmtab</i> (SI) | BENZTROPINE MESYLATE | 50 |
| | <i>Aclin</i> (AF) | BENZYDAMINE HYDROCHLORIDE | 25 |
| | <i>Aclin 200</i> (AF) | BENZYLPENICILLIN | 33 |
| | <i>Aclor 125</i> (AW) | BETAMETHASONE ACETATE WITH | |
| | <i>Aclor 250</i> (AW) | BETAMETHASONE SODIUM PHOSPHATE | 30 |
| | ADRENALINE | <i>Bgramin</i> (GM) | 32 |
| | Cardiovascular system | <i>Bicillin L-A</i> (AS) | 33 |
| | Respiratory system | <i>Brufen</i> (AB) | 42 |
| | <i>Alepam 15</i> (AF) | C | |
| | <i>Alepam 30</i> (AF) | CARBAMAZEPINE | 50 |
| | <i>Alodorm</i> (AF) | <i>Carbamazepine Sandoz</i> (SZ) | 50 |
| | <i>Alphamox 125</i> (AF) | <i>Ceclor</i> (AS) | 37 |
| | <i>Alphamox 250</i> (AF) | <i>Ceclor CD</i> (AS) | 37 |
| | <i>Alphamox 500</i> (AF) | CEFACTOR | 37 |
| | <i>Amohexal</i> (HX) | <i>Cefaclor-GA</i> (GN) | 37 |
| | <i>Amoxil</i> (GK) | <i>Cefaclor Sandoz</i> (SZ) | 37 |
| | Special Pharmaceutical Benefits | <i>Cefalexin Sandoz</i> (SZ) | 36 |
| | Antiinfectives for systemic use | CEFALOTIN | 35 |
| | <i>Amoxil Forte</i> (GK) | <i>Cefalotin Sandoz</i> (SZ) | 35 |
| | AMOXYCILLIN | CEFOTAXIME | 38 |
| | Special Pharmaceutical Benefits | <i>Cefotaxime Sandoz</i> (SZ) | 38 |
| | Antiinfectives for systemic use | CEFUROXIME AXETIL | 38 |
| | <i>Amoxycillin-DP</i> (GM) | <i>Celestone Chronodose</i> (SH) | 30 |
| | <i>Amoxycillin Ranbaxy</i> (RA) | <i>Cephabel</i> (BF) | 36 |
| | <i>Amoxycillin Sandoz</i> (SZ) | CEPHALEXIN | 36 |
| | AMOXYCILLIN WITH CLAVULANIC ACID | <i>Cephalexin Max</i> (XF) | 36 |
| | AMPHOTERICIN | <i>Cephatrust 250</i> (MI) | 36 |
| | AMPICILLIN | <i>Cephatrust 500</i> (MI) | 36 |
| | <i>Anamorph</i> (FM) | <i>Chem mart Amoxycillin</i> (CH) | 31 |
| | <i>Anaprox 550</i> (RO) | <i>Chem mart Amoxycillin and Clavulanic Acid</i> (CH) | 35 |
| | <i>Anginine Stabilised</i> (SI) | <i>Chem mart Cefaclor</i> (CH) | 37 |
| | <i>Antenex 2</i> (AF) | <i>Chem mart Cefaclor CD</i> (CH) | 37 |
| | <i>Antenex 5</i> (AF) | <i>Chem mart Cephalexin</i> (CH) | 36 |
| | <i>APO-Amoxycillin/ Clavulanic Acid 500/125</i> (TX) | <i>Chem mart Chemadol</i> (CH) | 49 |
| | <i>APO-Amoxycillin</i> (TX) | <i>Chem mart Diclofenac</i> (CH) | 41 |
| | <i>APO- Paracetamol/Codeine 500/30</i> (TX) | <i>Chem mart Doxycycline</i> (CH) | 31 |
| | <i>APO-Paracetamol</i> (TX) | <i>Chem mart Piroxicam</i> (CH) | 42 |
| | <i>APO-Temazepam</i> (TX) | <i>Chem mart Tramadol</i> (CH) | 48 |
| | <i>APO-Tramadol SR</i> (TX) | <i>Chem mart Tramadol SR</i> (CH) | 48 |
| | <i>Arthrexin</i> (AF) | CHLORAMPHENICOL | 53 |
| | <i>Aspen Ampicyn</i> (AS) | <i>Chloromycetin</i> (PF) | 53 |
| | ASPIRIN | <i>Chlorsig</i> (SI) | 53 |
| | ATROPINE SULFATE | <i>Cilamox</i> (SI) | 31 |
| | <i>Augmentin</i> (GK) | <i>Cilex</i> (GM) | 36 |
| | <i>Augmentin Duo</i> (GK) | <i>Cilicaine</i> (SI) | 33 |
| | <i>Augmentin Duo 400</i> (GK) | <i>Cilicaine V</i> (FM) | 33 |
| | <i>Augmentin Duo forte</i> (GK) | <i>Cilicaine VK</i> (FM) | 33 |
| | <i>Austrapen</i> (LN) | <i>Cilopen VK</i> (GM) | 33 |
| B | | <i>Clamoxyl</i> (AL) | 35 |
| | <i>Bactrim</i> (RO) | <i>Clamoxyl Duo</i> (AL) | 34 |
| | <i>Bactrim DS</i> (RO) | <i>Clamoxyl Duo 400</i> (AL) | 35 |
| | | <i>Clamoxyl Duo forte</i> (AL) | 35 |
| | | <i>Clavycillin 875/125</i> (CR) | 35 |

GENERIC/PROPRIETARY INDEX

| | | | |
|--|----|---|----|
| <i>Cleocin (KR)</i> | 39 | <i>E-Mycin (AF)</i> | 38 |
| CLINDAMYCIN | 39 | <i>E-Mycin 200 (AF)</i> | 38 |
| <i>Clonac 25 (AW)</i> | 41 | <i>E-Mycin 400 (AF)</i> | 38 |
| <i>Clonac 50 (AW)</i> | 41 | <i>Endone (SI)</i> | 47 |
| <i>Codalgin Forte (FM)</i> | 44 | <i>Eryc (HH)</i> | 38 |
| <i>Codapane Forte (AL)</i> | 44 | <i>Erythrocin-I.V. (LM)</i> | 38 |
| CODEINE PHOSPHATE | 44 | ERYTHROMYCIN | 38 |
| CODEINE PHOSPHATE WITH PARACETAMOL | 44 | ERYTHROMYCIN ETHYL SUCCINATE | 38 |
| <i>Cogentin (FK)</i> | 50 | ERYTHROMYCIN LACTOBIONATE | 38 |
| <i>Comfarol Forte (SZ)</i> | 44 | | |
| <i>Cortef (DT)</i> | 29 | F | |
| <i>Cortic-DS 1% (FM)</i> | 29 | <i>Febridol (GM)</i> | 49 |
| <i>Crysanal (MD)</i> | 43 | <i>Feldene (PF)</i> | 42 |
| <i>Curam (SZ)</i> | 35 | <i>Feldene-D (PF)</i> | 42 |
| <i>Curam 500/125 (SZ)</i> | 34 | <i>Fenac (AF)</i> | 41 |
| <i>Curam 875/125 (SZ)</i> | 35 | <i>Fenac 25 (AF)</i> | 41 |
| <i>Curam Duo (SZ)</i> | 35 | <i>Flagyl (SW)</i> | 39 |
| | | <i>Flagyl S (SW)</i> | 40 |
| D | | <i>Flopen (AS)</i> | 34 |
| <i>Dalacin C (PH)</i> | 39 | <i>Flubiclox (TS)</i> | 34 |
| <i>DBL Doxycycline (FA)</i> | 31 | <i>Flucil (AS)</i> | 34 |
| <i>DBL Erythromycin (FA)</i> | 38 | FLUCLOXACILLIN | 34 |
| <i>DBL Metronidazole Intravenous Infusion (HH)</i> | 40 | <i>Fungilin (BQ)</i> | 25 |
| <i>Depo-Medrol (PH)</i> | 30 | | |
| <i>Depo-Nisolone (KR)</i> | 30 | G | |
| DIAZEPAM | 51 | <i>GA-Amclav 500/125 (GM)</i> | 34 |
| <i>Diazepam-DP (GM)</i> | 51 | <i>GA-Amclav Forte 875/125 (GM)</i> | 35 |
| <i>Diclocil (BQ)</i> | 33 | <i>GenRx Amoxicillin (GX)</i> | 31 |
| <i>Diclofenac-GA (GN)</i> | 41 | <i>GenRx Amoxicillin and Clavulanic Acid (GX)</i> | 35 |
| DICLOFENAC SODIUM | 41 | <i>GenRx Cefaclor (GX)</i> | 37 |
| <i>Diclohexal (SZ)</i> | 41 | <i>GenRx Cefaclor CD (GX)</i> | 37 |
| DICLOXACILLIN | 33 | <i>GenRx Cephalexin (GX)</i> | 36 |
| <i>Dicloxsig (SI)</i> | 33 | <i>GenRx Diclofenac (GX)</i> | 41 |
| <i>Difflam (IA)</i> | 25 | <i>GenRx Doxycycline (GX)</i> | 31 |
| <i>Dilaudid (MF)</i> | 44 | <i>GenRx Piroxicam (GX)</i> | 42 |
| <i>Dilaudid-HP (MF)</i> | 44 | <i>GenRx Tramadol (GX)</i> | 48 |
| <i>Dinac (GM)</i> | 41 | <i>GlucaGen Hypokit (NO)</i> | 30 |
| <i>Distaph 250 (AF)</i> | 33 | GLUCAGON HYDROCHLORIDE | 30 |
| <i>Distaph 500 (AF)</i> | 33 | GLUCOSE | 27 |
| <i>Dolaforte (CO)</i> | 44 | GLYCERYL TRINITRATE | 28 |
| <i>Doryx (HH)</i> | 31 | | |
| <i>Douglas Cefaclor-CD (GM)</i> | 37 | H | |
| <i>Doxsig (SI)</i> | 31 | HYDROCORTISONE ACETATE | 29 |
| <i>Doxy-100 (GM)</i> | 31 | HYDROCORTISONE SODIUM SUCCINATE | 30 |
| DOXYCYCLINE | 31 | HYDROMORPHONE HYDROCHLORIDE | 44 |
| <i>Doxyhexal (SZ)</i> | 31 | | |
| <i>Doxylin 100 (AF)</i> | 31 | I | |
| <i>Ducene (SU)</i> | 51 | <i>Ialex (LN)</i> | 36 |
| <i>Durotram XR (IA)</i> | 48 | <i>Ibilex 125 (AF)</i> | 36 |
| <i>Dymadon P (PC)</i> | 49 | <i>Ibilex 250 (AF)</i> | 36 |
| | | <i>Ibilex 500 (AF)</i> | 36 |
| E | | | |
| <i>E.E.S. 200 (LM)</i> | 38 | | |
| <i>E.E.S. 400 Filmtab (LM)</i> | 38 | | |
| <i>E.E.S. Granules (LM)</i> | 38 | | |

GENERIC/PROPRIETARY INDEX

| | | | |
|---|----|---|----|
| <i>Ibimicyc</i> (TS) | 33 | <i>Moxiclav Duo 500/125</i> (AW) | 34 |
| IBUPROFEN | 42 | <i>Moxiclav Duo Forte 875/125</i> (AW) | 35 |
| <i>Indocid</i> (AS) | 41 | <i>MS Contin</i> (MF) | 46 |
| INDOMETHACIN | 41 | <i>MS Contin Suspension 100 mg</i> (MF) | 46 |
| <i>Inza 250</i> (AF) | 43 | <i>MS Contin Suspension 20 mg</i> (MF) | 46 |
| <i>Inza 500</i> (AF) | 43 | <i>MS Contin Suspension 30 mg</i> (MF) | 46 |
| J | | <i>MS Contin Suspension 60 mg</i> (MF) | 46 |
| <i>Jurnista</i> (JC) | | <i>MS Mono</i> (MF) | 46 |
| 45 | | <i>Murelax</i> (FM) | 51 |
| K | | <i>Mycostatin</i> (BQ) | 25 |
| <i>Kapanol</i> (GK) | | N | |
| <i>Karlor CD</i> (LN) | | NALOXONE HYDROCHLORIDE | |
| <i>Keflex</i> (AS) | | 54 | |
| <i>Keflin Neutral</i> (AS) | | <i>Naloxone Min-I-Jet</i> (CS) | |
| <i>Keflor</i> (AF) | | 54 | |
| <i>Keflor CD</i> (AF) | | <i>Naprosyn</i> (RO) | |
| <i>Kenacort-A10</i> (BQ) | | 43 | |
| KETOPROFEN | | <i>Naprosyn SR1000</i> (RO) | |
| 43 | | <i>Naprosyn SR750</i> (RO) | |
| L | | 43 | |
| LIGNOCAINE HYDROCHLORIDE | | NAPROXEN | |
| 28 | | 43 | |
| <i>Lincocin</i> (PH) | 39 | NAPROXEN SODIUM | |
| LINCOMYCIN | 39 | 43 | |
| <i>LPV</i> (AS) | 33 | <i>Nilstat</i> (SI) | |
| <i>Lycinate</i> (FM) | 28 | 25 | |
| M | | . Alimentary tract and metabolism | |
| <i>Maxamox</i> (SZ) | | 26 | |
| <i>Maxolon</i> (VT) | | NITRAZEPAM | |
| 25 | | 51 | |
| METHYLPREDNISOLONE ACETATE | | <i>Normison</i> (SI) | |
| 30 | | 51 | |
| METOCLOPRAMIDE HYDROCHLORIDE | | NYSTATIN | |
| 25 | | 25 | |
| <i>Metrogyl 200</i> (AF) | 39 | . Alimentary tract and metabolism | |
| <i>Metrogyl 400</i> (AF) | 39 | 26 | |
| METRONIDAZOLE | 39 | O | |
| METRONIDAZOLE BENZOATE | 40 | <i>Ordine 10</i> (MF) | |
| <i>Metronidazole Sandoz</i> (SZ) | 40 | 45 | |
| <i>Metronide 200</i> (AV) | 39 | <i>Ordine 2</i> (MF) | |
| <i>Metronide 400</i> (AV) | 39 | 45 | |
| <i>Mobilis 10</i> (AF) | 42 | <i>Ordine 5</i> (MF) | |
| <i>Mobilis 20</i> (AF) | 42 | 45 | |
| <i>Mobilis D-10</i> (AF) | 42 | <i>Orudis</i> (SW) | |
| <i>Mobilis D-20</i> (AF) | 42 | 43 | |
| <i>Mogadon</i> (VT) | 51 | <i>Orudis SR 200</i> (SW) | |
| <i>Momex SR 10</i> (SI) | 46 | 43 | |
| <i>Momex SR 100</i> (SI) | 46 | <i>Oruvail SR</i> (AV) | |
| <i>Momex SR 30</i> (SI) | 46 | 43 | |
| <i>Momex SR 60</i> (SI) | 46 | OXAZEPAM | |
| MORPHINE HYDROCHLORIDE | 45 | 51 | |
| MORPHINE SULFATE | 45 | OXYCODONE | |
| <i>Moxacin</i> (AS) | 32 | 47 | |
| | | OXYCODONE HYDROCHLORIDE | |
| | | 47 | |
| | | <i>OxyContin</i> (MF) | |
| | | 47 | |
| | | <i>OxyNorm</i> (MF) | |
| | | 47 | |
| | | <i>OxyNorm Liquid 5mg/5mL</i> (MF) | |
| | | 47 | |
| | | <i>Ozcef</i> (RA) | |
| | | 37 | |
| P | | | |
| <i>Panadeine Forte</i> (SW) | | 44 | |
| <i>Panamax</i> (SW) | | 49 | |
| <i>Panamax 240 Elixir</i> (SW) | | 49 | |
| PARACETAMOL | | 49 | |
| <i>Paracetamol Sandoz</i> (SZ) | | 49 | |
| <i>Paralgin</i> (FM) | | 49 | |
| <i>Pharmacy Choice Paracetamol</i> (YM) | | 49 | |
| PHENOXYMETHYLPENICILLIN | | 33 | |
| PIROXICAM | | 42 | |

GENERIC/PROPRIETARY INDEX

| | | | |
|--|----|--|----|
| <i>Pramin (AF)</i> | 25 | <i>Terry White Chemists Paracetamol (TW)</i> | 49 |
| PROCAINE PENICILLIN | 33 | <i>Terry White Chemists Piroxicam (TW)</i> | 42 |
| PROCHLORPERAZINE | 25 | <i>Terry White Chemists Tramadol (TW)</i> | 48 |
| <i>Prodeine Forte (AV)</i> | 44 | <i>Terry White Chemists Tramadol SR (TW)</i> | 48 |
| <i>Proladone (PL)</i> | 47 | TICARCILLIN WITH CLAVULANIC ACID | 35 |
| PROMETHAZINE HYDROCHLORIDE | 26 | <i>Timentin (GK)</i> | 35 |
| <i>Proxen SR 1000 (MD)</i> | 43 | TRAMADOL HYDROCHLORIDE | 48 |
| <i>Proxen SR 750 (MD)</i> | 43 | <i>Tramahexal SR (SZ)</i> | 48 |
| R | | <i>Tramal (CS)</i> | 48 |
| | | <i>Tramal 100 (CS)</i> | 49 |
| <i>Rafen 200 (AF)</i> | 43 | <i>Tramal SR 100 (CS)</i> | 48 |
| <i>Rancef (RA)</i> | 36 | <i>Tramal SR 150 (CS)</i> | 48 |
| <i>Ramoxoy (RA)</i> | 32 | <i>Tramal SR 200 (CS)</i> | 49 |
| <i>Ranzepam (RA)</i> | 51 | <i>Tramal SR 50 (CS)</i> | 48 |
| <i>Resprim (AF)</i> | 38 | <i>Tramedo (AF)</i> | 48 |
| <i>Resprim Forte (AF)</i> | 38 | <i>Tramedo SR 100 (AF)</i> | 48 |
| | | <i>Tramedo SR 150 (AF)</i> | 48 |
| S | | <i>Tramedo SR 200 (AF)</i> | 49 |
| | | TRIAMCINOLONE ACETONIDE | 30 |
| <i>Seprin (SI)</i> | 38 | TRIMETHOPRIM WITH SULFAMETHOXAZOLE | 38 |
| <i>Seprin Forte (SI)</i> | 38 | | |
| <i>Serepax (SI)</i> | 51 | V | |
| <i>Sigmacort (SI)</i> | 29 | | |
| SODIUM CHLORIDE | | <i>Valium (RO)</i> | 51 |
| .Blood and blood forming organs | 27 | <i>Valpam 2 (SI)</i> | 51 |
| .Variou | 54 | <i>Valpam 5 (SI)</i> | 51 |
| SODIUM CHLORIDE WITH GLUCOSE | 27 | <i>Vancocin CP (AS)</i> | 39 |
| <i>Solprin (RC)</i> | 49 | VANCOMYCIN | 39 |
| <i>Solu-Cortef (PH)</i> | 30 | <i>Vancomycin Sandoz (SZ)</i> | 39 |
| <i>Sporahexal (HX)</i> | 36 | <i>Vibramycin (PF)</i> | 31 |
| <i>Staphylex 250 (AF)</i> | 34 | <i>Voltaren 100 (NV)</i> | 41 |
| <i>Staphylex 500 (AF)</i> | 34 | <i>Voltaren 25 (NV)</i> | 41 |
| <i>Stemetil (SW)</i> | 25 | <i>Voltaren 50 (NV)</i> | 41 |
| <i>Stemzine (AV)</i> | 25 | | |
| SULINDAC | 42 | Z | |
| T | | | |
| | | <i>Zinnat (GK)</i> | 38 |
| <i>Tegretol 100 (NV)</i> | 50 | <i>Zydol (AW)</i> | 48 |
| <i>Tegretol 200 (NV)</i> | 50 | <i>Zydol SR 100 (AW)</i> | 48 |
| <i>Tegretol CR 200 (NV)</i> | 50 | <i>Zydol SR 150 (AW)</i> | 48 |
| <i>Tegretol CR 400 (NV)</i> | 50 | <i>Zydol SR 200 (AW)</i> | 49 |
| <i>Tegretol Liquid (NV)</i> | 50 | | |
| <i>Temaze (AF)</i> | 51 | | |
| TEMAZEPAM | 51 | | |
| <i>Temtabs (FM)</i> | 51 | | |
| <i>Teril (AF)</i> | 50 | | |
| <i>Terry White Chemists Amoxycillin (TW)</i> | 31 | | |
| <i>Terry White Chemists Amoxycillin and Clavulanic Acid (TW)</i> | 35 | | |
| <i>Terry White Chemists Cefaclor (TW)</i> | 37 | | |
| <i>Terry White Chemists Cefaclor CD (TW)</i> | 37 | | |
| <i>Terry White Chemists Cephalixin (TW)</i> | 36 | | |
| <i>Terry White Chemists Diclofenac (TW)</i> | 41 | | |
| <i>Terry White Chemists Doxycycline (TW)</i> | 31 | | |